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Applications of EphB4 receptor specific peptides in targeted cancer imaging and therapy
Publication No. ________
Miao Huang, M.S.
Supervisory Professor: Chun Li, Ph.D.
EphB4 receptors, a member of the largest family of receptor tyrosine kinases, are
found over-expressed in a variety of tumors cells including glioma cells as well as
angiogenic blood vessels. Noninvasive imaging of EphB4 could potentially increase
early detection rates, monitor response to therapy directed against EphB4, and improve
patient outcomes. Targeted delivery of EphB4 receptor specific peptide conjugated
hollow gold nanoshells (HAuNS) into tumors has great potential in cancer imaging and
photothermal therapy. In this study, we developed an EphB4 specific peptide named
TNYL-RAW and labeled with radioisotope 64Cu and Cy5.5 dye. We also conjugate this
specific peptide with hollow gold nanoshells (HAuNS) to evaluate targeted photothermal
therapy of cancers. In vitro,

64

Cu-DOTA-TNYL- RAW specifically bind to CT26 and

PC-3M cells but not to A549 cells. In vivo, Small-animal PET/CT clearly showed the
significant uptake of

64

Cu-DOTA-TNYL-RAW in CT26 and PC-3M tumors but not in

A549 tumors. Furthermore, µPET/CT and near-infrared optical imaging clearly showed
the uptake of the dual labeled TNYL-RAW peptide in both U251 and U87 tumors in the
brains of nude mice. In U251 tumors, Cy5.5-labeled peptide can bind to EphB4expressing tumor blood vessels and tumors cells. But in U87 models, dual labeled
peptide only could bind to tumor associated blood vessels. Also, Irradiation of PC-3M
and CT-26 cell treated with TNYL-PEG-HAuNS nanopatilces with near-infrared (NIR)

iv

laser resulted in selective destruction of these cells in vitro. EphB4 targeted TNYL-PEGHAuNS showed more photothermal killing effect on CT26 tumor model than PEGHAuNS did. In summary, tumors with overexpression of EphB4 receptors can be
noninvasively visualized by micro PET/CT with

64

Cu labeled or dual labeled TNYL-

RAW peptide. Targeted delivery of TNYL-RAW conjugated HAuNS into tumors can
greatly improve the treatment effect of photothermal therapy. The information acquired
with this study should be advantageous in improving diagnostics and future applications
in photothermal ablation therapy in clinical.
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INTRODUCTION
1. Ephrin receptors
1.1 Ephrin receptor families
A tyrosine kinase (erythropoietin-producing human hepatocellular carcinoma
receptor, Eph receptor) was first discovered by Hirai et al (Science) in 1987. In a
screening for novel oncogenic tyrosine kinase, Hirai cloned a new gene from a
carcinoma cell line that was named EphA1 later. They also found that this novel receptor
tyrosine kinase is up-regulated in tumor versus normal tissues. Ectopic overexpression
this kinase can cause the oncogenic transformation of NIH3T3 fibroblasts (1, 2) , which
suggested the oncogenic function of Eph gene. Later, the corresponding ligand (ephrin
A1) of Eph A1 receptor was also identified from cancer cell lines. Eph receptors
comprise the largest family of vertebrate receptor tyrosine kinases (3). It is now known
that there are 9 Eph A and 5 Eph B receptors which promiscuously bind to 5
glycosylphosphatidylinositol (GPI)-linked ephrin-A ligands and GPI-linked 3 ephrin-B
ligands respectively (4). But Eph A4 and Eph B2 receptors can also bind to ephrin-B or
ephrin A5 ligands respectively. EphB4 receptor preferentially binds to ephrin B2 ligand.
The signal transduction between Ephrin receptors and ephrin ligands is bidirectional.
Tyrosine kinase activity determined forwarding signal is amplified and propagated in the
receptor expressing cells and Src family kinase determined reversed signal is propagated
in ephrin ligand expressing cells. However, the ephrin ligand-dependent but tyrosine
kinase independent signaling pathway can also be found at some conditions (5-7). The
activation of most receptor tyrosine kinases depends on the dimerization of receptors
once ligand-receptor complex formed. But the activation of Ephrin receptor-ephrin
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ligand complex is different from the classic activation way of receptor tyrosine kinases
(8). Multimerization of ephrin ligand molecules on cellular membranes plays an
important role in Ephrin/Eph function (9, 10). The signaling pathway of Eph/ephrin
complex is well understood in the development process of nervous system such as in
axon plasticity and patterning, which can be explained by repulsive mechanism. The
Ephrin receptor expressed axons can migrate away from cells that express ephrin ligand
based on this repulsive mechanism (10). There are lots of signal transduction pathways
and downstream molecules involved in the Eph/ephrin receptor signaling axis, such as
JAK/ STAT (11) and AKT/PI3K pathways (12).
1.2 Biology functions of Ephrin receptor families
Ephrin receptors play an important role in numbers of biological processes in normal
development such as axon guidance, cell migration, cell morphology, cell adhesion,
invasion, angiogenesis and limb development (13, 14). The signal through Eph receptors
can influence the cell migration, adhesion and invasion by modifying the structures of
actin cytoskeleton and affecting the activities of intercellular adhesion molecules and
integrins (4, 15). Eph receptors are also involved in some specialized cell function such
as insulin secretion, immune function and bone remodeling (15).
A lot of evidence has been accumulated to demonstrate that Eph/ephrin axis plays
significant roles in the development of vasculature. The distinct expression pattern of
Eph B4 receptor and its ligand ephrin B2 on arterial and venous endothelial cells suggest
that developing capillary networks may not be uniform structures (16). The essential
requirement for tumor growth and survival is the formation of new blood vessels and
capillaries from pre-existing vasculature networks (angiogenesis). Studies have implied
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that up-regulation and dysregulation of Eph/ephrin axis signaling pathway involved in
the new blood vessels formation during the process of the tumor invasion (1, 17, 18)
Lots of studies have shown that the expression level of Ephrin receptors and ephrin
ligands is correlated with the cancer progression, invasion, metastasis and the survival
rate of patients (17-27). For example, EphA2 receptor has been found overexpressed in
numbers of cancers and its expression level is correlated with the progression of cancer
and poor prognosis of cancer patients (17-21). Also, among all the cancer types, the
expression of EphA2 receptor is preferable in the breast and prostate cancers with a
basal phenotype (22, 23). Studies have shown that up-regulation of Eph A2, A7, A10
and ligands such as ephrin A2 and B3 is involved in the breast cancer invasion and
metastasis (24). Up-regulated expression level of Eph receptors and their ephrin ligands
is correlated with the progression of malignant melanoma (25) Eph A1 not only can
promote the proliferation of melanoma cancer cells and enhance the cancer cell growth,
it also can increase the angiogenesis in advanced melanomas (26). Ectopic
overexpression of Eph A2 can promote progression of benign prostatic epithelial cells
into more aggressive phenotype (27).
EphB4 receptors play important roles in a variety of biologic processes, including
cell aggregation and migration, neural development, embryogenesis and angiogenesis,
and limb development (13, 28-31). Overexpression of EphB4 receptor, an important
member of Ephrin family, has been observed in numerous tumor types, including breast
prostate, bladder, lung, colon, ovarian, and gastric cancers (4, 32-36). Endogenous
ligand, eprin-B2, can specifically bind to its corresponding receptor EphB4 to promote
progression and metastasis of various cancers and induce angiogenesis in more advanced
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cancers. The effect of promotion of tumorigenesis and angiogenesis is mediated through
the signaling interaction between EphB4 and ephrin B2 ligand. It is interesting to notice
that some forwarding EphB4 signaling pathway may exhibit the inhibit effect on tumor
cell proliferation.(37) Xia et al. demonstrated that EphB4 is up-regulated in prostate
cancer cells and the induction of expression of EphB4 in prostate tumors may undergo
the transcriptional regulatory effect of pro-survival signaling molecules or through the
amplification of gene encode EphB4 receptor (38). Furthermore, inhibition of expression
and oncogenic activity of EphB4 can reduce the survival, migration and invasion of
prostate cancer cells. Another paper also showed that increased EphB4 activity and
expression in prostate cancer patients are correlated with the higher grade disease which
suggested that the expression level of EpHB4 indicate the malignancy of the disease (39).
In colon cancer, increased expression of the EphB4 gene has been found to play an
important role in the development of unique tumor phenotype (40). It has been also
found that EphB4 receptors are expressed at high levels in both tumor cells and blood
vessels in high-grade gliomas (41).
1.3 Develop EphB4 Specific peptides for molecular imaging
As above mentioned, EphB4 is overexpressed in various cancer types including
prostate, colon and brain tumors (38-41). So it is intriguing to develop a new molecular
imaging probes targeted for EphB4 receptors. But up to now, there is no peptide based
imaging probes being developed to detect EphB4 receptors in different tumors.
The most important thing for molecular imaging is to find a proper molecular target
to differentiate tumors from normal tissues. There are lots of pathologically abnormal
processes in cancer that allow us to make molecular imaging probes to target these
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processes for in vivo detection and functional characterization of tumors. Over the past
years, a lot of radiolabeled peptides used as nuclear imaging agents have been developed
for in vivo visualization of solid tumors with overexpressed receptors. For example,
radiolabeled neuropeptide receptors ligands are suitable molecular targeting probes for
in vivo visualization of tumors with overexpression of corresponding receptors by
positron emission tomography (PET) or single photon emission computed tomography
(SPECT) (42,43). In clinic, small radiolabeled somatostatin peptidyl analogs (molecular
weight ~1.5 kDa) have been successfully developed for detection and visualization of
neuroendocrine tumors with overexpression of somatostatin receptors (42, 43). Currently,
cyclic Arg-Gly-Asp peptide which binds to integrin αvβ3 receptors used for nuclear
imaging is under clinical investigation (44). Lots of other peptide-based imaging agents,
such as substance P (45), melanocyte-stimulating hormone analog (46), calcitonin (47),
atrial natriuretic peptide (48), bombesin/gastrin-releasing peptide, cholecystokinin,
glucagonlike peptide-1, and neuropeptide-Y, have also been identified and developed for
in vivo molecular imaging of solid tumors (49). But very few peptides have been
characterized for noninvasive detection and imaging of prostate cancer, colon cancer and
gliomas (49).
Using phage display approach, several 12-mer peptides which specifically bind to
corresponding Ephrin receptors have been identified by Koolpe et al in 2005 (50).
Among those peptides, an Ephrin B4 receptor specific peptide (Thr-Asn-Tyr-Leu-PheSer-Pro-Asn-Gly-Pro-Ile-Ala, TNYL peptide) has been identified from initial screening.
To optimize this TNYL peptide, the original TNYL peptide has been modified by adding
a tripeptide moiety (RAW) at the carboxyl terminus based on the information from the
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sequence alignment. The final product, Thr-Asn-Tyr-Leu-Phe-Ser-Pro-Asn-Gly-Pro-IleAla-Arg-Ala-Trp (TNYLFSPNGPIARAW, TNYL-RAW) was show to be a strong
antagonist of EphB4 receptor. This modified peptide inhibited binding of ephrin B2, a
natural EphB4 binding ligand, to immobilized Eph4 receptor with IC50 around 15 nM
compared with 150 µM for TNYL peptide (50). In Koolpe’s study, the biotinylated
TNYL peptide was conjugated to streptavidin-coated quantum dots nanoparticles Qdot
655 quantum dots (Quantum Dot Corp.) to confirm the targeting effect of this peptide.
From his study, it has clearly showed that this TNYL conjugated quantum dots can
specifically bind to COS cells with ectopic expression of Eph B4 receptors or cells with
endogenous expression of EphB4 (50). Because TNYL-RAW peptide has extremely
high binding affinity for EphB4 receptors, we tried to investigate whether this peptide
can be used as molecular imaging agents to noninvasively detect and visualize upregulated EphB4 receptors in various tumor models. Furthermore, we conjugated this
peptide to hollow gold nanoshells (HAuNS) to study the effect of photothermal therapy
on colon and ovarian cancer model
2

Multimodal Imaging

2.1 Nuclear Imaging
The first time using of radioactive tracers in the living system was to study the
transport of radioactive lead in plants was done by Hevesy and Paneth in 1923. In 1935,
Hevesy and Chiewitz used radiotracer (P-32) to study the distribution of radioactive P32 in rats. Later, Anger invented the first scintigraphic imaging instrument named
gamma camera in 1956. At the same time, positron imaging was developed too. Now,
both imaging modalities become standard methods in nuclear medicine filed. The most
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radioisotopes used in the clinical settings are

99m

Tc in single photon imaging (SPCET)

and 18F in positron imaging (PET). Now, PET and SPECT techniques have become the
standard imaging diagnosis processes for the patients with different diseases. The
underlying mechanism in nuclear medicine is to use the radiotracers to detect the
metabolism, biochemical, physiological and pathophysiology process in patients. These
two imaging modalities can be used alone or combined together to study various
biological activities in human body such as metabolite rate, binding capacity and
transport rate. Also they can be used to monitor and detect the expression of enzymes,
receptors, and transporter as well as their corresponding endogenous analogue such as
ions, hormones, and enzyme substrates (51-53). Compared with other imaging
modalities, nuclear imaging has more advantages, such as more sensitive, deep
penetration into the tissues, and quantitative analysis and process of the image data. But
there is no perfect single imaging technique. Nuclear imaging can detect abnormal
physiology, biochemical or metabolic changes in patients but they may provide less
accurate location and anatomy structure of the human body due to the weak spatial
resolution of nuclear imaging. To provide more accurate anatomy location and structure
information of the patients, multimodality imaging devices such as PET/CT, SPECT/CT,
and PET/MRI are developed and become more popular in clinical practice. These
combinations of imaging techniques can provide precise 3-dimensional images of
biological and anatomical information in patients. Nuclear imaging may require long
acquisition time of imaging due to the low photon counts. Also, it doesn’t provide
sufficient resolution details in real time because of the short and finite half-life of the
radiotracer used (54, 55). Then optical imaging can be an alternative imaging technique.
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2.2 Optical Imaging
Optical imaging is a rapidly developing field and attracts lot of interest recently.
Biomedical optical imaging techniques can be used in various clinical diagnosis and
molecular biology and substantially affect the outcomes of treatment and prevention of
cancer (56). Optical imaging techniques such as fluorescence and bioluminescence
molecular imaging have lots of advantages compared with traditional imaging
techniques. First, they can provide high spatial resolution images to reflect both
functional and structural changes at nano or even femtomolar sensitivity (57). Secondly,
these techniques are non-invasive, non-radiation, portable and low cost. Third, the
results of optical imaging can be obtained almost in real time. Fourth, these techniques
can provide valuable information in both microscopic and macroscopic scales and
widely applied in almost all biomedical fields. Last but not the least, quantitative
analysis of optical imaging results can be useful for objective diagnosis and patient
follow-up.(58-63). Furthermore, these techniques have already been tested in various
initial clinical situations. For example, it is promising to use hemoglobin and
deoxyhemoglobin as a biomarker to monitor effective neo-adjuvant chemotherapy in
breast cancer patients by diffuse optical spectroscopy (64, 65).
The major limitations of further application of optical imaging techniques in
clinical settings are the penetration depth due to the strong scattering of optical radiation
in tissues and strong auto-fluorescence due to the absorbance of the photons by the thick
and opaque tissues. The acquired signal can be obscured by above reasons. However,
recent progress in NIR (near infrared region, 650-900 nm) optical techniques exhibits
promising in vivo application of optical imaging techniques. First, the detection depth of
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NIR has been pushed to a few centimeters. Second, NIR molecular imaging technique
shows lower light absorbance and reduced auto-fluorescence of normal tissues, which
makes it more suitable for in vivo application (66-70). In our studies, we labeled our
EphB4 specific peptide TNYL-RAW with NIR fluorophores (Cyanine 5.5 also called
Cy5.5) for in vivo optical molecular imaging in glioblastoma orthotopic nude mice
models. Cy5.5 is a fluorescent dye emitting photons in the NIR spectrum and one of the
members of synthetic cyanine dye family. This dye is water-soluble, and has an
absorbance maximum of 675 nm and an emission maximum of 694 nm.
2.3 Importance of Multimodal Imaging
Today, various imaging techniques are available for differential diagnosis and
evaluation of severity of diseases as wells as monitoring the therapeutic response of the
patients to medical treatments. Among all of these imaging modalities, such as positron
emission tomography (PET), single photon emission computed tomography (SPECT),
optical imaging, computed tomography (CT), ultrasound (71) and magnetic resonance
imaging (MRI), none of them can be used alone to provide sufficient comprehensive
information necessary for the diagnosis of various disease of patients. Multimodality
imaging can provide structure and functional information of the disease by two ways.
One is that images are acquired at different times and then different images are fused
together by digital imaging processing technique (asynchronous way). Another way
(synchronous way) is that images are acquired simultaneously and merged
automatically. It is difficult to fuse images using asynchronous way due to the two
different scans acquired at separated machines. The best solution to solve the
inconsistency of the space and time is achieved by using synchronous image acquisition.
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Currently, lots of multimodality techniques (SPECT/CT, PET/CT, and PET/MR) are
available in diagnostic imaging fields. The most common techniques among these are
combinations of high detection sensitivity techniques such as PET and SPECT with CT,
MRI, and ultrasound that have high spatial resolution. The first prototype of CT-SPECT
thoracic images of patients was obtained in 1962 (45). Since the commercial
introduction of SPECT/CT and PET/CT in 1998, the development and use of these
instruments grows exponentially. Up to now, there are almost no sales of standalone
PET machines and all PET sales are as part of multimodality systems (72).
As we all known, no single imaging modality is perfect. In current study we
combined the optical imaging technique, one of the most widely used imaging
techniques in preclinical molecular imaging with nuclear imaging PET/CT, which is the
most effective clinical imaging modality.
3

Hollow gold nanoshell
Optical phenomenon named surface plasmon resonance (SPR) is an important

characteristic of Au and silver (Ag) containing nanostructures. When these
nanomaterials are exposed to light, the conduction-band electrons in the metal
containing nanostructures will collectively oscillate at a resonance frequency relative to
the lattice of positive ions. Then the nanostructures will absorb the incident light at this
resonance frequency. The resonance of the solid spherical nanoparticles is about at 400
nm for Ag and around 520 nm for Au. The variable peak wavelength of absorbance
relatively depends on the size or the embedding medium of the nanoparticles. We can
tune the peak wavelength of SPR from visible to near infrared (NIR) region by changing
the size, shape, and structure of the nanoparticles.
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The novel Au containing

nanoparticles termed hollow gold nanospheres (HAuNS) have the unique characteristics
such as small size (30-60 nm), spherical shape, hollow interior, and strong and tunable
(520-950 nm) absorption band at NIR region (73, 74).
Using cobalt (Co) NPs as sacrificial templates to synthesize of HAuNSs with tunable
interior cavity sizes was first reported by Liang’s group (75). Due to the higher reduction
potential of the AuCl4-/Au redox pair (0.935 V vs the standard hydrogen electrode [SHE])
compared with that of the Co2+/Co redox couple (-0.377 V vs SHE), the Au3+Cl4- can be
easily reduced to Au (0) atoms once the Co nanoparticles are added into chloroauric acid
solution. The reaction equation is as this: 3Co+2AuCl4- = 2Au+ 3Co2++8Cl-. The size of
the final HAuNS product is controlled by the initial size of the Co nanoparticles template
because the reduced Au atoms are mostly confined to the vicinity of the outer surface of
the Co template. The stability of HAuNS is maintained by coating polyethylene glycol
(PEG) on the surface of the shells. Coating HAuNS with higher molecular-weight (5kDa)
makes HAuNS much more stable than coating with lower molecular weight (2kDa) PEG
does. Also HAuNS coated with thioctic-acid-anchored PEG containing two thiol groups
are more stable in aqueous solution than HAuNS coated with monothiol-anchored PEG.
4

Photothermal therapy
Photothermal therapy is a therapeutic method in which photothermal agent is

introduced to produce heat after the laser energy delivered to the targeted tumors. The
heat produced by this photothermal effect is far beyond the threshold temperature
(~330k) which can cause irreversible cell death and kill the tumor cells (76). This
therapy modality has attracted a lot of attentions recently because it has lots of
advantages over the traditional cancer therapies such as fewer side effect, less
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accumulated toxic effect with repeatedly laser treatments and boosted efficacy of the
chemotherapy and radiotherapy when combined with photothermal therapy (76-79).
Nanoparticles with unique optical properties such as gold nanoshells, nanorods,
nanocages, and hollow nanospheres (80-86) can significantly enhance the efficiency of
photothermal therapy by integrating these light-absorbing materials into the target tissue
to mediate the selective photothermal effects. HAuNS have the unique characteristics
such as small size (30-60 nm), spherical shape, hollow interior, and strong and tunable
(520-950 nm) absorption band (73, 74), which have the great opportunity to convert
optical energy into thermal energy for thermal ablation of tumor cells. It is possible to
deliver thermal energy to the deeper tissue because the SPR absorption peak of HAuNS
is the easily tunable in the NIR region. Due to the convenient modification of the surface
of the HAuNS, specific molecular targeting molecules with SH-terminal can be easily
conjugated to the Au surface of HAuNSs through covalent bonds. Lots of different
specific targeting molecules such as antibodies, peptides, and low molecular-weight
compounds have been conjugated to the surface of the HAuNS (73, 87). After
modification with the specific homing molecules, the HAuNS can be used in targeting
photothermal therapies in vitro and in vivo. Loo et al. (84) and Lowery

(88)

demonstrated targeted photothermal killing of human breast cancer cells in vitro when
irradiated with an NIR laser (820 nm) at 35 W/cm2 for 7 min but no effect on the dermal
fibroblast which don’t overexpress HER2 receptors on their surface by using HER2
(human epidermal growth factor receptor 2) specific antibody conjugated nanoshells
(89). It is well known that one of the most important factors for the cellular uptake of
nanoparticles is the size of the nanostructures. Nanoparticles larger than 100 nm are
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difficult for uptake into the cells and may interfere with the normal function of the cells.
The small particle size (smaller than 20 nm) may be difficult for cells to retain the
nanoparticles. For in vivo targeting of nanoparticles into tumor tissues, the particle size is
also a critical factor. It was demonstrated that the smaller size of gold nanoparticles (2040nm) coated with PEG has longer blood circulation time than lager gold nanoparticles
(80 nm). Also with the smaller size, gold nanoparticles has better chance of
extravasating from tumor-associated blood vessel into the extra-vascular fluid space and
passively diffused into the tumor tissues. Taken together, the idea size of the particle for
photothermal therapy in vitro and vivo is between 20 nm and 80 nm. The size of the
HAuNS we used in this study is around 40 nm. Previous study in our lab demonstrated
the selective killing EGFR over-expression of cancer cells A431 in vitro by introducing
C225 antibody (targeting EGF receptors) conjugated HAuNS into the tumor cells (73).
This killing effect is mediated through EGFR demonstrated by blocking or nonconjugated PEG coated HAuNS control studies. Wei et al. (85) conjugated HAuNS with
a small molecular-weight peptide, [Nle4, D-Phe7] a–melanocyte-stimulating hormone
(NDP-MSH) for successfully targeted photothermal therapy of melanoma in vitro and
vivo studies. Our lab previously reported using EphB4 receptor specific TNYL-RAW
peptide or peptide conjugated polymeric micellar nanoparticles to detect of EphB4
expression in cancer (90, 91). Therefore, targeting of EphB4 has great potential in cancer
imaging and therapy.

13

Specific Aims and Significance
Early detection of cancer and monitoring the treatment response of cancer patients by
molecular imaging methods are important components of the differential diagnosis of
cancer patients and prediction of prognosis of patients. It is desirable to have an imaging
method to accurately detect and monitor EphB4 status in cancer patients. Photothemal
therapy is a novel cancer treatment strategy that kills cancer cells by producing heat after
the laser energy delivered to the targeted tumors. Introduction of HAuNS into local
tumor tissues can enhance the photothermal therapy effect. EphB4 is a good targeting
molecule for specific delivery of HAuNS to tumor tissues.
Therefore, the major purpose in my study is: first, to develop a novel targeting peptide
molecules dual-labeled by Cy5.5 optical dyes and
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Cu nuclear isotopes for early

detection of tumors with the overexpression of Eph B4 receptors in vivo; Second,
synthesis and evaluation of photothermal killing effect of EphB4 specific peptide
conjugated HAuNS on the tumor cells in vitro and vivo. Using this novel imaging agent,
it allows us to do whole-body scan to visualize and locate tumor by nuclear imaging
(PET/CT) and followed by fluorescence imaging guided biopsies to define precisely
extent and region of local tumors. It is first time here to show that EphB4-specific
peptide could be used as a non-invasive molecular imaging agent for PET/CT or/and
optical imaging of tumors owing to its ability to bind to EphB4-expressing angiogenic
blood vessels and or to EphB4-expressing tumors. We believe that translation of this
discovery from basic science to clinical situation may improve the differential diagnosis
of cancer patients and affect the outcome of the prognosis of the patients. Conjugation of
EphB4 specific peptide onto the HAuNS can enhance the delivery HAuNS to local
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tumor tissues with overexpression of Eph B4 and mediate specific killing effects on
tumor cells by phothothermal therapy. We hope that our nanoparticles which conjugated
specific homing molecules can combine imaging and therapeutic functions together for
cancer diagnosis and treatments in future clinical medicine.
MATERIALS AND METHODS
1. Reagents
All amino acid derivatives and coupling reagents were purchased from Novabiochem
(San Diego, CA), Bachem (Torrance, CA), and Chem-Impex International (Wood Dale,
IL). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO). DOTATA was synthesized in our lab.
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CuCl2 solution was bought from University of

Wisconsin (Madison, WI). PC-3M cells were gift from Dr. Fiedler (UT MD Anderson
Cancer Center, TX). CT-26 and A549 cells were purchased from American Type
Culture Collection (Manassas, VA). U87 cells stably transfected with the luciferase gene
(U87-Luc) were gift from Dr. Gelovani (UT MD Anderson Cancer Center, TX). U251
cells were gift from Dr. Shuyun Huang (UT MD Anderson Cancer Center, TX). Hey A8
stably transfected with the luciferase gene (HEY A8-Luc) were gift from Dr. Anil Sood
(UT MD Anderson Cancer Center, TX). RPMI-1640, DMEM/F12 and MEM medium
were obtained from Gibco (Carlsbad, CA). Calcein AM, Eth-D1 and DAPI were
purchased from Invitrogen (Carlsbad, CA). PD-10 columns were purchased from
Amersham-Pharmacia Biotech (Piscataway, NJ). Protein assay kit was purchased from
Bio-rad (Hercules, CA) D-Luciferin was purchased from Biosynth Chemistry & Biology
(Staad, Switzerland). Rat anti-mouse CD31 antibody was purchased from Millipore
(Billerica, MA). Recombinant EphB4/Fc chimera, phycoerythrin-conjugated rat
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antihuman EphB4 monoclonal antibody, and rabbit anti-EphB4 antibody were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Goat anti-rabbit antibody conjugated
with near-infrared dye was purchased from Li-COR. DOTA was obtained from
Macrocyclics. The Biacore sensor chip CM5, amine coupling kit, HBSEP running buffer
(0.01 M 4-(2-hydroxyethyl)- 1-piperazineethanesulfonic acid [HEPES], pH 7.4; 0.15 M
NaCl; 3 mM ethylenediaminetetraacetic acid [EDTA]; and 0.005% [v/v] surfactant P20
solution), and regeneration buffer were purchased from Biacore, Inc.
2. General Procedures for the peptide synthesis
Solid phase syntheses of peptide were performed on the automatic peptide
synthesizer Prelude (PTI, Tucson, AZ) using Rink resin (Novabiochem). 5 × 1.5 mL of
dimethylformamide (DMF)/methylene chloride (CH2Cl2) was used to wash the resin
(0.05 – 0.1 g). 3 × 1.5 mL of 20% piperidine/DMF was used to remove
fluorenylmethyloxycarbonyl (Fmoc) groups for 5 min each. Three-fold excesses of
Fmoc-amino acids, diisopropylcarbodiimide (DIC), and HOBt (1-hydroxybenzotriazole)
were used in 3 mL of DMF/CH2Cl2 for coupling procedure. This procedure was repeated
once. Resins were washed with 3 × 3 mL of DMF/CH2Cl2 after coupling and
deprotection steps. Resins were washed with 3 × 3 mL of CH2Cl2 and treated with
trifluoracetic acid (TFA): triisopropylsilane: H2O (95:2.5:2.5) for 15 min each once the
procedure of peptide chain enlongation was finished. The combined filtrates sat at room
temperature for 1-2 hr, and the volumes were reduced in a vacuum. Peptides were
precipitated in ice-cold ethyl ether, washed 2 times with ethyl ether and collected by
centrifugation. After drying, peptides were purified by reverse-phase high-performance
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liquid chromatography (RP-HPLC) on an Agilent 1200 system (C-18, Vydac, 10 × 250
mm, 10 µm; Santa Clara, CA).
Solution phase reaction was used to synthesize DOTA and fluorescein
isothiocyanate (FITC)-coupled TNYL-RAW (Figure 3A) peptides followed by HPLC
purification.

For conjugation of Cy5.5 or/and DOTA to TNYL-RAW peptides, a

solution of Cy5.5-NHS (1eq) and peptide TNYL-RAW or DOTA-NHS (1eq) and
peptide TNYL-RAWK (Figure 8A) in dimethylformamide and DIPEA (10/1) were
stirred at room temperature overnight. A lysine group was introduced to the peptide
sequence before simultaneous conjugation of Cy5.5 and DOTA to the peptide due to the
C-terminal amide group in original peptide sequence. Before introduction of lysine
group, a glycine linker amino acid was added at c-terminal to minimize the effect on
binding affinity of peptide after modification of sequence. After the solvent was
removed under vacuum, the residual was purified by reverse-phase HPLC, eluted with a
0.01-M solution of NH4OAc in water and acetonitrile, and lyophilized. The peptides
were identified by high-resolution electrospray ionization mass spectrometry (HRMSESI) spectra acquired in the positive ion mode. This was done on an Agilent 1100 Series
LC/MSDTOF instrument equipped with a Vydac C18 column (4.6 x 250 mm, 7 µm, 300
Å) (Anaheim). For synthesis of PEG-TNYL-SATA (Figure 15A) peptide, the peptide
and heterodifunctional poly (ethylene glycol) (PEG) precursor, N-hydroxysuccinimidylPEG-S-acetylthioacetate (NHS-PEG-SATA; molecular weight 5,000, figure 15A) was
conjugated together, through peptide’s α-amine group of threonine residue and activated
ester in NHS-PEG-SATA. The sulfhydryl group on the other terminus of TNYL-PEGSATA was released by treatment with 0.05 M hydroxylamine in PBS.
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3. Synthesis of HAuNS
HAuNS were synthesized according to the method of Schwartzberg et al. with
minor modifications (70). Briefly, 2500 µL of sodium borohydride (1 M) was added into
1000 mL of deoxygenated aqueous solution of sodium citrate (2.8 mM) and cobalt
chloride (0.4 mM) to synthesize cobalt template nanoparticles. The clear and slightly
pink solution turned brown after adding sodium borohydride, which indicated reduction
of Co (II) and the formation of cobalt nanoparticles. The solution was left to stay at room
temperature for 45 min under constant gas flow of argon until complete hydrolysis of the
sodium borohydride. In a different vial, bubbling with argon gas was used to
deoxygenate 600 mL chloroauric acid (0.04 mM) solution. Then, 800 mL of cobalt
nanoparticle solution was transferred to the chloroauric acid solution under argon
protection and magnetic stirring. Gold ions were immediately reduced by cobalt onto the
surface of cobalt nanoparticles while at mean time cobalt was oxidized to cobalt oxide.
Any remaining cobalt core was further oxidized by air, resulting in the final formation of
HAuNS.
4. Conjugation of TNYL-PEG-SATA to HAuNS
The reaction scheme of conjugation of TNYL-PEG-SATA to the surface of HAuNS
is shown in Figure 15B. Briefly, TNYL-PEG-SATA (1mg/mL, 200 µL) solution was
treated with hydroxylamine (50mmoL/L, 50µL) in total volume of 500µL PBS
containing 10mM of EDTA (pH 7.0) before conjugation to HAuNS. The reaction
mixture was stirred at room temperature for about 2 h. Then the product (TNYL-PEGSH) was purified by passing through a PD-10 column (Amersham-Pharmacia Biotech,
Uppsala, Sweden) and eluted with PBS (pH 7.4). Therefore, the purified TNYL-PEG-SH
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was added into HAuNS (2x1012particles/mL) solution and stirred at room temperature
for about 6 hours. Then PEG-SH (5 mg/mL, 0.4 mL) was added into mixture and
allowed to react overnight at room temperature. The final product (TNYL-PEG-HAuNS)
was purified by centrifuging at 8,000 rpm for 15 minutes and the pellet was resuspended
with PBS. This process was repeated twice to remove excess peptide and free PEG-SH
molecules. The purified TNYL-PEG-HAuNS was sent to the core facility in Baylor
College of medicine to do the amino acid analysis. PEG-SH was conjugated to HAuNS
similarly to above procedure to give PEG-HAuNS, which was used as a nonspecific
control.
5. Photothermal Effect of different HAuNS solutions
The photothermal effect of HAuNS solutions was measured as previously described.
Briefly, the laser was a continuous wave GCSLX-05-1600m-1 fiber-coupled diode laser
(Newport model 840-C). A 5-m 600-Am core BioTex LCM-001 optical fiber was used
to transfer laser light from the laser unit to the target. The laser spot size of the lens
mounting at the output could be changed by changing the distance from the output to the
target. The output power was separately calibrated by a handheld optical power meter
(Newport model 840-C) and was found to be 1 W for a spot diameter of 3.5 mm (8
W/cm2) and a 2-amp supply current. NIR laser light (808 nm) was delivered through a
quartz cuvette containing the nanoshells (100 µL) to heat HAuNS and its derivatives. A
thermocouple was inserted into the solution perpendicular to the path of the laser light to
measure the temperature changes mediated by NIR laser light. The temperature was
measured over a period of 15 min.
6. In vitro Photothermal Ablation of Tumor cells
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PC-3M, CT-26 and Hey A8-Luc cells were seeded onto a 96-well plate with a density
of 1x105 cells per well one day before the experiment. Cells were washed three times
with culture medium without phenol red and FBS. The following groups were used: NIR
laser alone, TNYL-PEG-HAuNS plus laser, PEG-HAuNS plus laser, TNYL-PEGHAuNS with excess TNYL-PEG peptide (blocking group) plus laser. For treated with
HAuNS, cells were incubated with PEG-HAuNS or TNYL-PEG-HAuNS (100 µL,
2x1011 particles/mL) at 37oC for 2 hours. For blocking group, cells were co-incubated
with TNYL-PEG-HAuNS with excess amount of TNYL-PEG peptide. After incubation,
cells were washed three times with PBS to remove nonspecific binding of or unbound
HAuNS. Cells were re-cultured in DMEM/F12 medium without phenol red
supplemented with 10%FBS. Then cells were irradiated with near IR-region laser light
centered at 808nm at an output power 40 W/cm2 for 5 min (15PLUS laser, Diomed) and
incubated at 37 oC for additional 24 h. The diode laser was coupled to a 1-m, 2-mm core
fiber, which delivered a circular laser beam of 2mm in diameter to cover the central area
of the microplate well. Power calibration was done automatically. Cells were washed
three times with HBSS (Hank’s balanced salt solution) and stained with calcein AM
(green color) for detection of viable cells and Eth-D1 (red color) for detection of dead
cells 24 h after the laser treatment. Cells were visualized under the Zeiss Axio
Observer.Z1 fluorescence microscope (Carl Zeiss MicroImaging GmbH, Germany).
7. Radiolableing
For Radiolabeling of DOTA-TNYL-RAW and peptides, 64CuCl2 (74–148 MBq [2–4
mCi]) in 0.1 M sodium acetate (pH 5.2) was added to 10 µg aqueous solution of DOTATNYL-RAW or Cy5.5-TNYL-RAW-DOTA. The reaction mixture was incubated at
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70°C for 1 h. The progress of the reaction was monitored by reversed-phase highperformance liquid chromatography (RP-HPLC) with a radiodetector. EDTA was added
into the solution to terminate the reaction. The 64Cu-labeled peptide was further purified
by RP-HPLC on an Agilent 1100 system (C-18, Vydac; 4.6 · 250 mm, 10 mm) and
eluted at a linear gradient of 10%–90% acetonitrile in a 0.1% aqueous trifluoroacetic
acid solution over 35 min at a flow rate of 1.0 mL/min.
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Cu-DOTA-TNYL-RAW and

64

Cu-DOTA-TNYL-RAW-Cy5.5 peptides were collected in 1- to 2-mL fractions. The

solvent was then removed, reconstituted in saline and passed through a 0.22-mm filter
for using in the animal experiments. Natural copper chloride (natCuCl2) was used to
synthesize

nat

Cu-DOTA-TNYL-RAW under identical conditions. High-resolution

electrospray ionization mass spectrometry was used to confirm the identity of
DOTA-TNYL-RAW.
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Cu-DOTA-TNYL-RAW was co-injected with

nat

nat

Cu-

Cu-DOTA-

TNYL-RAW into the HPLC system, which was equipped with both ultraviolet and
radiodetectors to confirm its identity.
For conjugation of
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Cu to nanoparticles, DOTA-TA (1 mg/mL, 10 µL) was mixed

with 1 mL aqueous solution of HAuNS (4×1012 particles/mL) for 4 h at room
temperature. The following conjugation of TNYL-PEG-SH and/or PEG-SH to AuNS,
and purification was the same as above described. For radiolabeling, aliquots of TNYLPEG-HAuNS-DOTA) or PEG-HAuNS-DOTA (4×1012 particles/mL, 0.5 mL) in 0.1
mol/L sodium acetate solution (pH 5.5) were mixed with an aqueous solution of 64CuCl2
(~2 mCi) for 30 min. The radiolabeled nanoparticles were then purified by centrifugation
at 8,000 rpm for 5 min and washed three times with PBS. The radiolabeling efficiency
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and the stability of labeled nanoparticles were analyzed using instant thin layer
chromatography (ITLC).
8. Immobilization of EphB4 receptor to sensor chip
10 mM sodium acetate buffer at pH 4.5 was used to dilute the stock solution (100
µg/ml, in PBS) of EphB4/Fc into three different concentrations of solutions (25, 12.5,
and 6.25 µg/ml). The diluted solution was immobilized to a CM5 sensor chip using the
amine coupling reaction following manufacturer-provided procedures (BIACORE).
Briefly, the surfaces of the chips in flow cells (FC)-1, -2, -3, and -4 were activated by
exposing them to a mixture of 200 mM N-ethyl-N’-dimethylaminopropyl carbodiimide
(EDC) and 50 mM N-hydroxysuccinimide (NHS) for 7 min. FC-1 was used as a
reference surface and deactivated by directly injecting of 1 M ethanolamine at pH 8.5 for
7 min. The other three flow cells were injected with 25 µg/ml, 12.5 µg/ml, and 6.25
µg/ml EphB4/Fc solutions respectively and followed by injection of 1 M ethanolamine
to block the remaining activated ester groups on the surface. Before injection of samples,
the chip was allowed to stabilize for at least 2 h in HBSEP running buffer.The
sensogram of immobilized EphB4 on CM-5 sensor chips were shown in figure 2A. The
mechanism of coupling of EphB4 receptor to CM5 sensor chip is shown in figure 2B.
9. Surface Plasmon Resonance (SPR) Assay of Receptor Binding Affinity
Binding assays were performed at 25ºC in HBSEP running buffer. The peptides were
diluted in HBSEP buffer, filtered, degassed, and injected at concentrations between 1.6
nM and 800 nM at a flow rate of 30µl/min. The injection time of peptides into the
HBSEP buffer was 4 min, followed by a 4-min dissociation period. After each binding
cycle, the chips were regenerated using a 1-min pulse of 10 mM glycine (pH 2.2). Each
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cycle consisted of a 1-min waiting period to allow monitoring of the baseline binding
stability for subtraction of bulk effects caused by changes in the compositions of buffer
or nonspecific binding. Because we performed double referencing, all samples were
additionally injected onto an uncoated reference surface, including a sample of the
running buffer, which was also tested on the EphB4/Fc coated flow cell. Data were
evaluated with BIAevaluation software (version 3.0, BIACORE), applying a simple 1:1
binding mass transfer model. The obtained sensorgrams were fitted globally over the
whole range of injected concentrations for both the association and dissociation phases.
Equilibrium dissociation constants were then calculated from the rate constants (KD =
koff/kon) (90).
10. Stable transfecetion of Luciferase gene into U251 cells (U251-Luc)
U251 cells were seeded in the 6-well plates (5x105 cells/well) and incubated
overnight at 37°C in a humidified incubator in an atmosphere of 5% CO2 24h before the
experiment. 2ml DMEM/F12 medium (without FBS) with 50ul Cignal™ Lenti Positive
Control (luc) viral particles (8µg/mL polybrene) were added into the well after culture
medium was removed. The plates were gently swirled to mix the solution. 6‐8 hours
later, the viral supernatant (from the first infection) from the wells was removed and the
cells were re-infected with 2mL of fresh supernatant (with polybrene 8µg/ml). The next
day, viral supernatant was removed and DMEM/F12 with 10% FBS was added back to
the cells. 72 hours after incubation, the cells were sub-cultured into 100mm dishes and
the puromycin (1µg/ml) was added into cells to select the cells expressing luciferase.
After 1 week selection, luciferase activity of the selected positive cells was tested by
Xenogen IVIS-200 Optical in Vivo Imaging System (Caliper Life Sciences).
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11. Fluorescence and Darkfield microscopy
For peptide binding study, PC-3M, CT26, or A549 cells were seeded (1x105/well) in
Lab-Tek II–chambered slides (Nalge Nunc International) supplemented with
DMEM/F12 medium plus 10% FBS 24h before the experiment.

The cells were

incubated with 100 µL of phenol-free DMEM/F12 culture medium with addition of 10
µM FITC-TNYL-RAW or scrambled FITC-scTNYL-RAW (AGPFNTYLRINAWSP)
for 20 min at room temperature. For the blocking experiment, 10 µM FITC-TNYLRAW and 1 mM TNYL-RAW were simultaneously added to the cells and incubated for
half an hour at 37°C. For detection of EphB4 expression, cells were fixed with 4%
paraformaldehyde for 20 min and washed 3 times with PBS, then incubated with 50 µL
of phycoerythrin-conjugated rat anti-human EphB4 monoclonal antibody (R&D Systems)
or rabbit anti-human EphB4 polyclonal antibody (1:100 dilustion) in PBS at 4°C
overnight. For polyclonal antibody, goat anti-rabbit antibody conjugated with Alexa
flour 488 was used as secondary antibody (1:500 dilutions). The cell nuclei were
counterstained with DAPI. After washing with PBS, the slides were mounted and
visualized under an Axiovert Z.1 fluorescent microscope (Zeiss).
For nanoparticles binding study, PC-3M and CT-26 Cells were seeded at density of
2x 105 per well in 24 wells plate with coverslip in each well 24 h before experiment. The
culture medium was removed and cells were washed with HBSS twice. Then the culture
medium without FBS was added back into the cells. 2x1011particles/mL of PEG-HAuNS
or TNYL-PEG-HAuNS were added into each well and incubated for 2 hours at 37 ºC.
For blocking group, excess amount of free TNYL-PEG peptide (1 mg) was added with
TNYL-PEG-HAuNS into cells as a control. After incubation, cells were washed with
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cold PBS 3 times and counterstained with 4, 6-diamidino-2-phenylindole (DAPI; Sigma,
Saint Louis, MO). Then the cells were fixed in 4% paraformaldehyde solution in 20 min
at room temperature and washed with PBS 3 times. Cells on coverslip were mounted
with mounting medium (Dako, CA) onto slides. The slides were examined under a
fluorescence microscope with a dark-filed condense to determine the binding of TNYLPEG-HAuNS particles to tumor cells. Cells without adding nanoparticles were used as
background control.
12. Cell binding
For peptide uptake study, CT26, PC-3M, and A549 cells were grown in 6-cm Petri
dishes as described before (25). The culture medium was replaced with 2 mL
DMEM/F12 culture medium without FBS containing
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Cu-DOTA-TNYL-RAW (~1.48

MBq/mL [~20µCi/mL], 100 nM). Cells were incubated with radiolabeled peptides at
room temperature for 30, 60, or 120 min. For the blocking experiment,
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Cu-DOTA-

TNYL- RAW peptide (~1.48 MBq/mL [~40µCi/mL], 100 nM) was co-incubated with
TNYL-RAW (10 µM) under the same conditions. Thereafter, the monolayer of cells
were scraped and transferred into 5-mL tubes. The tubes were briefly stirred at a vortex
mixer, and 100 µL of the cell suspension were transferred into a micro-centrifuge tube
containing 500 µL of a 75:25 mixture of silicon oil (density, 1.05; Sigma-Aldrich) and
mineral oil (density, 0.872; Acros). The mixture was centrifuged at 14,000 rpm for 5 min.
After the tubes were snap-frozen in liquid nitrogen, the bottom tips containing the cell
pellet were cut off. The cell pellets and supernatants were counted by a Packard Cobra
Quantum g-counter (GMI) seperately. The protein content in a 100-µL of cell
suspension was quantified using the Bio-Rad protein assay kit according to the
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manufacturer’s protocol. The radioactivity in the cell pellets and medium was counted,
and the data were expressed as activity ratios of the cell pellet to the medium
([counts/min/mg of protein in pellet]/[counts/min/mg of medium]). The experiments
were performed in pentaplicate.
For Nanoparticles uptake study, PC3-M and CT-26 cells were seeded on 6 cm petri
dish at 1x106 densities in MEM or RPMI-1640 (Gibco, Carlsbad, CA) supplemented
with 10% fetal bovine serum and antibiotics (100 units/mL penicillin, 0.1mg/mL
streptomycin, Biochrom AG, Holliston, MA). Cells were allowed to grow at 37oC in a
humidified atmosphere with 5% CO2 overnight. On the experiment day, cell culture
medium was replaced with 2mL of fresh medium without FBS containing 2x1011
particles/mL 64Cu-TNYL-PEG-HAuNS or 64Cu-PEG-HAuNS (~2.0 MBq/mL) and cells
were incubated for 2 h. After incubation, the supernatant were removed and the cells
were washed with cold PBS for three times to remove non-specific binding of particles.
The cells were then trypsinized and resuspended in culture medium. The cell suspension
(100 µL) and the supernatants (100 µL) were counted with a gamma counter (PerkinElmer, Waltham, Massachusetts). The protein concentration of 100 µl cells was
quantified in s separate experiment using the Bio-Rad protein assay kit according to the
manufacture’s protocol. Activity of the cell suspensions to supernatant ([cpm/µg of
protein in cells]/ [cpm/µg of medium] were calculated and plotted against time. The
experiments were performed in pentaplicate.
13. Animal Models
All animal studies were performed under the guidelines and approval of the MDACC
Institutional Animal Care and Use Committee. Athymic nude mice (4–6 wk old, both
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sexes) were obtained from Harlan Laboratories. For mice subcutaneous tumor model,
CT26, PC-3M, and A549 cells were grown in DMEM/F12 supplemented with 10% FBS,
penicillin (100 IU/mL), and streptomycin (100 mg/mL) (Invitrogen) at 37 ˚ C in a
humidified atmosphere with 5% CO2. The cells were harvested by trypsinization. After
centrifugation of the cell suspension at 5,000 rpm for 5 min, the culture medium was
aspirated and the cell pellet was resuspended in PBS for subcutaneous injection in the
right front leg of each mouse. When the size of tumor reached around 1 cm in diameter,
small-animal PET/CT and biodistribution analysis were performed.
For orthotopic tumor model, Male nude mice (8-10 weeks old; Charles River
Laboratories) were used for the imaging experiments. Human glioblastoma U87 cells
(1x106) or U251 (3x106) stably transfected with the luciferase gene (U87-TGL) were
implanted in the brain of nude mice (1 mm right to and 2.5 mm behind the bregma, and
3 mm of depth) with a small animal stereotaxic device (David Kopf Instruments). The
mice were received intravenous injection of D-luciferin (4 mg/kg, Biosynth Chemistry &
Biology, Staad, Switzerland) 10 days after tumor inoculation. For ovarian cancer HeyA8 tumor model, 1 million tumor cells were intraperitoneally injected into nude mice.
Tumor burden as measured by luciferase activity was measured by using Xenogen IVIS200 Optical in Vivo Imaging System (Caliper Life Sciences) for bioluminescence
imaging (BLI). The bioluminescence signal generated in mice was imaged and
quantified using the LIVINGIMAGE V.2.11 software and IGOR image analysis
software (V.4.02 A, WaveMetrics). Region of interest (ROI) was manually selected and
signal intensity expressed in terms of number of photons/sec.
14. Small-Animal PET/CT
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Mice bearing PC-3M tumors (n=4 EphB4-positive), CT26 tumors (n =4; EphB4positive), or A549 tumors (n=4; EphB4-negative) were imaged with small-animal
PET/CT at various times after intravenous injection of 7.4 MBq (200 µCi) of 64CuDOTA-TNYLRAW (0.5–1µg). For the blocking group, the tumor-bearing mice (n=2)
were co-injected with 7.4 MBq (200 µCi) of

64

Cu- DOTA-TNYL-RAW and cold

TNYL-RAW peptide at a concentration of 50 µg/mouse. Images were acquired using an
Inveon PET/CT system (Siemens). The spatial resolution of the PET system is
approximately 1.4 mm. Tumor-bearing mice were anesthetized with isoflurane (2% in
oxygen) and placed prone. The CT parameters were as follows: x-ray voltage, 80 kVp;
anode current, 500 mA; and exposure time of each of the 360 rotational steps, 300–350
ms. Images were acquired at 1, 4, and 24 h after intravenous administration of

64

Cu-

DOTA-TNYL-RAW. Images were reconstructed using the 2-dimensional orderedsubsets expectation maximization algorithm. PET and CT image fusion and image
analysis were performed using Inveon Research Workplace (Siemens Preclinical
Solutions). In order to calculate tumor voxel intensity, an irregular 3-dimensional region
of interest (ROI) was manually drawn to cover the whole tumor on CT and then copied
to the corresponding PET images. A circular ROI was drawn on the muscle of the legs.
An ROI was also drawn on a standard (radiotracer solution containing 1% of the
injection dose) placed along with the animals. The mean activities within the ROI of the
tumor and muscle were calculated in an IRW workstation (Siemens).
Mice bearing U251 tumors (n=4 were imaged with small-animal PET/CT at various
times after intravenous injection of 7.4 MBq (200 µCi) of

64

Cu-Cy5.5-TNYLRAW-

DOTA (0.5–1 µg). For the blocking experiment, the U251 tumor-bearing mice (n =3)
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were coinjected with 7.4 MBq (200 µCi) of

64

Cu-Cy5.5-TNYL-RAW-DOTA and cold

Cy5.5-TNYL-RAW-DOTA peptide at a dose of 50 µg/mouse. Images were acquired
using an Inveon PET/CT system (Siemens). Tumor-bearing mice were anesthetized with
isoflurane (2% in oxygen) and placed prone. The CT parameters were as follows: x-ray
voltage, 80 kVp; anode current, 500 mA; and exposure time of each of the 360 rotational
steps, 300–350 ms. Images were acquired at 1 and 24 h after intravenous administration
of 64Cu-Cy5.5-TNYL-RAW-DOTA. Images were reconstructed using the 2-dimensional
ordered-subsets expectation maximization algorithm. PET and CT image fusion and
image analysis were performed using Inveon Research Workplace (Siemens Preclinical
Solutions). For tumor voxel intensity calculation, an irregular 3-dimensional region of
interest (ROI) was manually drawn corresponding to PET images. A circular ROI was
drawn on the normal brain part An ROI was also drawn on a standard (radiotracer
solution containing 1% of the injection dose) placed along with the animals. The mean
activities within the ROI of the tumor and normal brain were calculated in an IRW
workstation (Siemens).
15. Micro-PET imaging
CT-26 tumors were grown subcutaneously in the right thigh of the female nude
mice (20-25 g; Harlan Sprague Dawley, Indianapolis, IN) by injection of 1x 106 tumor
cells suspended in PBS. One week after inoculation, when tumor reached approximately
8-10 mm in diameter, mice were divided into 2 groups (n=3). Mice (group 1) were
intravenously injected 64Cu-TNYL-PEG-HAuNS and mice (group 2) were injected with
64

Cu-PEG-HAuNS (1x1011 particles/mouse, 200 µCi/mouse; 0.2 mL). The mice were

anesthetized with 2% isoflurane and placed in the prone position, and micro-PET
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imaging was acquired at 1 h, 6 h, and 24 h after injection of the radiolabeled
nanoparticles using an R4 microPET unit (Siemens Medical Solutions USA, Inc.), which
has an approximate resolution of 2 mm in each axial direction. Mice were maintained
under anesthesia with 1%–2% isoflurane, and a heating lamp was used to maintain their
body temperature during acquisition. Small-animal PET images were reconstructed with
the ordered-subsets expectation maximization algorithm using 16 subsets and 4
iterations.
16. Near Infrared (NIR) Optical Imaging
Mice bearing U87 tumors (n =4) or U251 tumors (n=4) were imaged with Xenogen
IVIS-200 Optical in Vivo Imaging System (Caliper Life Sciences) at various times after
intravenous injection of 10µg of

64

Cu-Cy5.5-TNYL-RAW-DOTA or

64

Cu-Cy5.5-

scramble peptide. Cy5.5 fluorescence filter set (excitation 615-665 nm, emission 695770 nm, background 580-610 nm) was applied. After mice were sacrificed, the
fluorescence signal of different organs and tumors were analyzed by Living Imaging
LIVINGIMAGE V.2.11 software and IGOR image analysis software (V.4.02 A,
WaveMetrics). Region of interest (ROI) was manually selected and signal intensity
expressed in terms of number of photons/sec.
17. In Vivo Biodistribution studies
For nude mice subcutaneous tumor models, nude mice bearing PC-3M, CT26, and
A549 xenografts (n =4/group) were injected with 0.74 MBq (20 µCi, 50 ng) of

64

Cu-

DOTA-TNYL-RAW peptide to evaluate the biodistribution of the radiotracer. For the
blocking experiment, the tumor-bearing mice (n=4) were coinjected with 0.74 MBq (20
µCi) of 64Cu-DOTA-TNYL-RAW and 200-fold cold TNYL-RAW peptide. The animals
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were sacrificed at 4 and 24 h after injection. The organs of interest were excised and
weighed and their radioactivity was counted by an automatic g-counter (GMI). The
stomach and intestines were not emptied before radioactivity measurements. The
percentage of injected dose per gram of tissue (%ID/g) was calculated by dividing
the %ID organ by the weight of the organ. Values were expressed as mean±SD.
Mice bearing CT-26 tumors were prepared as described previously. When the tumor
reached 4-6 mm in diameter, the mice were randomly assigned into 2 groups (n=6).
Mice (group 1) were intravenously injected
2) were intravenously injected with

64

64

Cu-TNYL-PEG-HAuNS and mice (group

Cu-PEG-HAuNS (1x1011 particles/mouse, 20

µCi/mouse; 0.2 mL). Mice were killed by CO2 overexposure 24 h after injection of
radiolabeled nanoparticles. Blood, heart, liver, spleen, kidney, lung, stomach, intestine,
muscle, bone, brain, and tumor tissues were removed and weighed, and the radioactivity
was measured with a gamma counter (Perkin-Elmer, Waltham, Massachusetts). Uptakes
of

64

Cu-labeled HAuNS in various organs were expressed as percentages of injected

dose per gram of tissue (%ID/g).
For HEY A8-Luc intraperitoneal model, 1x 106 cells were intraperitoneally injected
into mice. Tumor burden on mice was monitored by bioluminance activity. After tumor
reached to 0.2 to 1cm, the he mice were randomly assigned into 2 groups (n=6). Mice
(group 1) were intravenously injected
were intravenously injected with

64

64

Cu-TNYL-PEG-HAuNS and mice (group 2)

Cu-PEG-HAuNS (1x1011 particles/mouse, 20

µCi/mouse; 0.2 mL). Mice were killed by CO2 overexposure 24 h after injection of
radiolabeled nanoparticles. Blood, heart, liver, spleen, kidney, lung, stomach, intestine,
muscle, bone, brain, and tumor tissues were removed and weighed, and the radioactivity
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was measured with a gamma counter (Perkin-Elmer, Waltham, Massachusetts). Uptakes
of

64

Cu-labeled HAuNS in various organs were expressed as percentages of injected

dose per gram of tissue (%ID/g).
18. Autoradiography and Optical Imaging
Mice brains containing U251 tumors were harvested at the end of the imaging
session were snap-frozen and sectioned into 4-µm sections. The sections were
photographed and exposed onto BAS-SR 2025 Fuji phosphorus films. The film was
scanned with a FLA5100 Multifunctional Imaging System (Fujifilm Medical Systems
USA, Stamford, CT). After autoradiography study, optical images of the sections were
acquired by scanning at 800 nm using an Odyssey infrared imaging system (LI-COR
Biosciences, Lincoln, NE).
19. H&E staining and Immunohistochemical Analysis
For nude mice subcutaneous tumor models, after the small-animal PET/CT studies
were completed, the mice were sacrificed and the tumors were excised, snap-frozen, and
cut into 4-µm sections. For immunohistochemical analysis, frozen tumor sections were
fixed in 4% paraformaldehyde solution for 20 min at room temperature and washed with
PBS 3 times. Tumor sections were blocked with 10% goat serum for 30 min at room
temperature, and the slides were then incubated with rabbit anti-EphB4 antibody (U-200,
1:100 dilution) in PBS at 4˚C overnight. After incubation with primary antibody, slides
were washed with PBS 3 times and incubated with secondary goat antirabbit antibody
conjugated with Alexa Flour 488 (1:500 dilution; Invitrogen). Slides were washed again
in PBS and counterstained with DAPI. Microphotographs were taken under a Zeiss
Axiovert Z.1 fluorescence microscope with the same conditions and displayed at the
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same scale to make sure that the relative brightness observed in the images reflected the
difference in EphB4 expression level.
After the small-animal PET/CT and near infrared optical studies were completed, the
mice were sacrificed and tumors in mice brains were excised, snap-frozen and cut into 4mm sections. For immunohistochemical analysis, frozen tumor sections were fixed in
4% paraformaldehyde solution for 20 min at room temperature and washed with PBS 3
times. Tumor sections were blocked with 10% goat serum for 30 min at room
temperature, and the slides were then incubated with rabbit anti-EphB4 antibody (U-200,
Santa Cruz Biotech, CA, 1:100 dilution) and rat anti-mouse CD31 (Millipore,Billerica,
MA, 1;50 dilution) in PBS at 4˚C overnight. After incubation with primary antibody,
slides were washed with PBS 3 times and incubated with secondary goat anti-rabbit
antibody conjugated with Alexa Flour 488 (1:500 dilution; Invitrogen) and donkey antirat antibody conjugated with Alexa Flour 594 (1:500 dilution; Invitrogen). Slides were
washed again in PBS and counterstained with DAPI. Frozen blocks were sent to the core
histology facility in MD Anderson Cancer Center for H&E staining. Microphotographs
were taken and visualized by a Zeiss AxioCam MRc5 color camera.
20. Photothermal Ablation of Cancer Cells with TNYL-PEG-HAuNS in Vivo
Nude mice were inoculated subcutaneously with 1x106 CT-26 cells in the right side
of the rear legs 10 days before the experiment. When tumor growth reached 7-10 mm in
diameter, mice were randomly assigned into 4 groups (n=5). Mice (group 1) were
intravenously injected with TNYL-PEG-HAuNS (2x1012 per mouse, 200 µL); Mice
(group 2) were injected with PEG-HAuNS (2x1012 per mouse, 200 µL); Mice (group 3)
were injected saline as control; Mice (group 4) were not received any treatment. The
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tumors from groups 1, 2, 3 were irradiated with NIR laser at 3W/cm2 for 3 minutes 24 h
after injection of nanoparticles. The mice were killed 24 h after the laser treatment, then
the tumor was removed and cryosectioned into 5-µm sections for H&E staining. The
slides were visualized under a Zeiss Axio Observer.Z1 fluorescence microscope. The
images were taken using a Zeiss AxioCam MRc5 color camera.
Nude mice were inoculated with 1x106 Hey-A8-Luc cells intraperitaneally 14 days
before experiments. Tumor growth was monitored by luciferase activity. Mice were
randomly assigned into 3 groups. Mice (group 1) were injected with PEG-HAuNS
(2x1012 per mouse, 200 µL). Mice (group 2) were injected saline as control. Mice (group
3) were not received any treatment. The abdomens of mice bearing tumors were cut and
open, and then tumors were exposed. Because tumors grown in mice belly as multiple
nodules, so some nodules were used as internal control. 24 h after injection of
nanoparticles, the tumors from groups 1 and 2 were irradiated with NIR laser at 2W/cm2
for 3 minutes. The mice were killed 24 h after the laser treatment, and then the tumors
and normal tissue around the tumors treated with laser were removed and cryosectioned
into 5-µm sections for H&E staining. The slides were visualized under a Zeiss Axio
Observer.Z1 fluorescence microscope. The images were taken using a Zeiss AxioCam
MRc5 color camera.
21. Statistical Analysis
Statistical analysis was performed with GraphPad Prism v4.0 software (La Jolla, CA).
Unless otherwise stated, group comparisons were made using standard ANOVA
methods. Groups with P < 0.05 were considered statistically significant.
RESULTS
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1.

Synthesize and evaluate

64

Cu-labeled TNYL-RAW peptides for PET

imaging of EphB4 receptors in prostate and colon cancer xenograft models
1.1 Chemistry, Radiochemistry, and Stability
Figure 1A shows the structure of
scheme for the synthesis of

nat

nat

Cu/64Cu-DOTA-TNYL-RAW. The reaction

Cu/64Cu-DOTA-TNYL-RAW is shown in Figure 1B.

TNYL-RAW, DOTA-TNYL-RAW or FITC-TNYL-RAW was eluted as a single peak
with a retention time of 13.8 min, m/z =1,705.7764 for [M+H]
calculated [M+H]

+

+

(C80H117N22O20,

: 1,705.8814); 12.6 min, m/z =2,092.0554 for [M+H]

+

(C96H143N26O27, calculated [M+H]+: 2,092.0616) and 15.6 min, m/z= 2,094.9003 for
[M+H] + (C101H128N23O25S, calculated [M+H] +: 2,094.9172) respectively. The formation
of the

nat

Cu (II)-labeled complex

nat

Cu-DOTA-TNYL-RAW was confirmed by mass

spectrometry (Figure 1C), with m/z=1,076.9957 for [M+Cu]2+ (C96H143CuN26O27,
calculated [M+Cu]2+: 1,076.9917).

nat

Cu-DOTA-TNYL-RAW (ultraviolet detector) and

64

Cu-DOTA-TNYL-RAW (radiodetector) had almost identical retention times (12.5 and

12.6 min, respectively) under the similar HPLC condition (Figure 1D.) The
radiochemical purity of 64Cu-DOTA-TNYL-RAW (the ratio of the main product peak to
all peaks) was determined by HPLC to be more than 95%. The specific activity of 64CuDOTA-TNYL-RAW used in the in vitro and in vivo experiments was typically 7.4–14.8
MBq/nmol (0.2–0.4 Ci/mmol) at the end of synthesis. The stability of

64

Cu-DOTA-

TNYL-RAW was checked in culture medium (DMEM with 10%FBS) for up to 24 h at
37 ˚ C. Around 30% of the

64

Cu-DOTA-TNYL-RAW was degraded after 2 h of

incubation in culture medium at 37˚C.
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Figure 1A. Structure of 64Cu-DOTA-TNYL-RAW and natCu-DOTA--TNYL-RAW
peptides (peptide sequence: TNYLFSPNGPIARAW) (Reprinted with permission
p
of
(90))

Fig 1B.. Reaction scheme of synthesis of 64Cu/natCu-DOTA-TNYL-RAW
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Figure 1C. Electrospray ionization mass spectrometry spectrum of
TNYL-RAW (Reprinted with permission of (90))
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nat

Cu-DOTA-

Figure 1D. Radio-HPLC chromatogram of 64Cu-DOTA-TNYL-RAW (tR = 12.6 min)
compared with chromatogram of natCu-DOTA-TNYL-RAW (tR = 12.5 min) with UV
detection at 210 nm. (Reprinted with permission of (90))
1.2 Binding Affinity of TNYL-RAW and DOTA-TNYL-RAW-DOTA, NatCuDOTA-TNYL-RAW and scramble peptides
Figure 2A shows the sensogram of successful coating of EphB4 receptor on CM-5
sensor chip. Figure 2B shows the mechanism of coupling of EphB4 ligand to the surface
of the CM5 sensor chip. Figure 2C shows representative sensorgrams obtained from SPR
analyses of TNYL-RAW and DOTA-TNYL-RAW,

Nat

Cu-DOTA-TNYL-RAW and

scramble peptides with fitting curves obtained using a global 1:1 mass transfer model.
The corresponding binding kinetics and affinity data are summarized in Table 1. TNYLRAW had a KD of 3.06 nM. Conjugation of DOTA to the N terminus of the peptides
decrease the binding affinity, the KD value of the TNYL-RAW increased to 23.3 nM.
Interestingly, chelation of Cu2+ to the DOTA-TNYL-RAW restored the binding affinity
of peptides, with the KD value back to around 1.98 nM. Because we didn’t see response
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of scramble peptide to EphB4 receptor on SPR assay (Figure 2B), there was no
detectable binding ability of scramble peptides to the coated receptors.

Figure 2A. Sensogram of successful coating of EphB4 receptor on CM-5 sensor chip/
EDC/NHS was used to activation of chip. Ethnolamine was used to saturate unbound
site on the sensor chip.

O
OH

N

O

ligand

NH

O
EDC/NHS

C

ligand

O

C

O

NH2

C

O

Figure 2B. Mechanism of coupling of EphB4 ligand to the surface of CM5 sensor chip
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Figure 2C. SPR sensorgrams of TNYL-RAW and DOTA-TNYL-RAW-DOTA, NatCuDOTA-TNYL-RAW and scramble peptides on sensor chips coated with EphB4.
Peptides were injected as ten 2-fold-concentration series from 1.6 to 800 nM and were
analyzed in duplicate binding cycles. Datasets (shown in black) are overlaid with curves
fit to 1:1 mass transfer interaction model (red lines). Vertical axes in response units
represent binding of each peptide to immobilized EphB4. (Reprinted with permission of
(90))
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χ2

Analyte

kon [M-1S-1] koff [s-1]

KD [M]

TNYL-RAW

4.26×
×105

1.3×
×10-3

3.06×
×10-9 0.155

DOTA-TNYL-RAW

1.10×
×105

2.56×
×10-3

2.33×
×10-8 0.281

Nat

6.89×
×106

1.31×
×10-2

1.89×
×10-9 1.86

Cu-DOTATNYLRAW

Table 1. Association, Dissociation Rates and KD of different TNYL-RAW peptides and
derivatives interacting with immobilized EphB4 receptors obtained from SPR Analysis.
1.3 Fluorescence microscope
Previous papers have shown that the EphB4 receptors are overexpressed in prostate
and colon cancer cells (38, 40). Immunofluorescence study confirmed the positive
expression of EphB4 receptor on the surface of CT-26 and PC-3M cells after stained
with phycoerythrinconjugated rat antihuman EphB4 monoclonal antibody, but not on the
surface of EphB4-negative A549 cells (Fig3B). The structure details of FITC-TNYLRAW peptides were shown in Fig 3A. FITC-TNYL-RAW peptides (green color)
strongly bind to the surface of PC-3M and CT-26 cells, but not on the EphB4-negative
A549 cells. The specific binding of FITC-TNYL-RAW peptides to the CT-26 and PC3M cells were confirmed by the blocking or scramble peptide binding study which
showed that the binding of these FITC labeled peptides was efficiently blocked by coincubation with excess amount of TNYL-RAW peptides and there was no detectable
binding of FITC labeled scramble peptides binding to those EphB4 positive peptides.
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Fig 3A The structure details of FITC
FITC-TNYL-RAW

Figure 3B. Fluorescence photomicrographs of PC
PC-3M cells treated with FITC-TNYLFITC
RAW (10 µM, green) or scrambled peptide FITC
FITC-sc-TNYL-RAW
RAW (10µM, green) for 20
min at room temperature. Cells were also stained with phycoerythrin
phycoerythrin-conjugated
conjugated antianti
EphB4 antibody (red) for expression of EphB4 receptors. For blocking experiment,
FITC-TNYL-RAW (10 µM) was coincubated with TNYL-RAW (1mM).
mM). Cell nuclei
were counterstained with DAPI (blue). Bar =20 µm.
m. (Reprinted with permission of (90))
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1.4 In vitro radioisotope binding assay
64

Cu-DOTA-TNYL-RAW peptides were highly uptake by CT-26 and PC3-M cells.

The uptake of radiolabeled peptides of these cells was increased with time from 30min
to 2 hours. The specific binding of these peptides can be efficiently blocked by adding
excess amount of cold peptide TNYL-RAW and the total binding was decreased by
around 10 fold at all time points (Figure 4A and 4B).

Figure 4A. Uptake of 64Cu-DOTA-TNYL-RAW in EphB4-positive PC-3M cells. Cellto medium uptake ratio is expressed as (counts/ min/mg of protein in
pellet)/(counts/min/mg of medium). 64Cu-DOTA-TNYL-RAW showed increased uptake
over time in PC-3M cells. * Indicates the p value <0.005. (Reprinted with permission of
(90))
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Figure 4B. Uptake of 64Cu-DOTA-TNYL-RAW in EphB4-positive CT-26 cells. Cell-to
medium uptake ratio is expressed as (counts/ min/mg of protein in
pellet)/(counts/min/mg of medium). 64Cu-DOTA-TNYL-RAW showed increased uptake
over time in PC-3M cells. * Indicates the p value <0.005. (Reprinted with permission of
(90))
1.5 Small animal Micro PET/CT
Figure 5A showed the micro PET/CT results of nude mice bearing tumors after tail
vein injection of 64Cu-DOTA-TNYL-RAW. CT-26 tumors were clearly visualized at 1h
and 4 h after injection of 64Cu labeled TNYL-RAW peptides. But for PC-3M tumors, the
highest uptake of

64

Cu-DOTA-TNYL-RAW time point was 24 h after injection of

radiolabeled peptides. There was very low uptake of

64

Cu-DOTA-TNYL-RAW in

EphB4 negative A549 cells. According to the ROI calculations described in the above
methods, the uptake of

64

Cu-DOTA-TNYL-RAW in CT26 tumors was rapid, from

1.3 %ID/g at 1h post injection to 2.6 %ID/g at 4 h post injection, respectively. But the
level of tumor radioactivity in CT26 tumor was barely detectable at 24 h after injection
of radio tracer (Fig. 5A). The uptake values of

64

Cu-DOTA-TNYL-RAW in PC-3M

tumors were 1.4, 3.2, and 3.6 %ID/g at 1, 4, and 24 h after injection, respectively. The
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For EphB4-negative A549 tumors, the uptake of

64

Cu-DOTA-TNYL-RAW was at the

level of 1.7, 1.5, and 1.2 %ID/g at 1, 4, and 24 h after intravenous injection of
radiotracer. The summary of the different uptake of 64Cu-DOTA-TNYL-RAW in CT26,
PC-3M and A549 tumors at different time points was shown in table 2. We found that
the time point of highest uptake value of radio tracer is different in CT26 (4h post
injection) and PC-3M (24h post injection) tumors in vivo based on our micro PET/CT
results, so we chose different time points to do blocking study for CT26 (4h post
injection) and PC-3M (24h post injection) tumors. Uptake of 64Cu-DOTA-TNYL-RAW
in CT26 tumors was blocked by co-injection of excess amount of cold TNYL-RAW
peptides (50µg/mouse) (micro PET/CT images were taken at 4h post injection of radio
tracers). The specific uptake of radiotracer in PC-3M tumors was efficiently blocked by
co-injection of excess amount of cold TNYL-RAW peptide (50µg/mouse) (micro
PET/CT images were taken at 24h post injection of radio tracers). Based on the
calculations of ROI, the co-injection of cold peptides caused about 77% and 81%
reduction in 64Cu-DOTA-TNYL-RAW uptake in CT-26 and PC-3M tumors respectively.
(ROI of tumor (non-block)-ROI of tumor (block)/ ROI of tumor (non-block)).
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Figure 5A. Representative small-animal PET/CT imaging of mice bearing CT26, PC3M, and A549 tumors after tail vein injection of 64Cu-DOTA-TNYL-RAW (n=4).
Arrows indicate different tumors (PC-3M, CT26 and A549). (Reprinted with permission
of (90))
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Figure 5B. Representative micro PET/CT images showed the uptake of 64Cu-DOTATNYL-RAW was blocked in CT26 tumors at 4 h and in PC-3M tumors at 24 h after coinjection of 64Cu-DOTA-TNYL-RAW with cold TNYL-RAW (50µg/mouse). Arrows
indicate tumors. (Reprinted with permission of (90))

Tumor Type

1h

4h

24h

CT26

1.3%

2.6%

N/A

PC-3M

1.4%

3.2%

3.6%

A549

1.7%

1.5%

1.2%

Table 2 Shows the summary of summary of the different uptake of 64Cu-DOTA-TNYLRAW in CT26, PC-3M and A549 tumors at different time points.
1.6 In vivo biodistribution
Figure 6A shows the biodistribution of

64

Cu-DOTA-TNYL-RAW at 24 h after

radiotracer administration in nude mice bearing PC-3M or A549 lung tumors. There was
significantly higher uptake of 64Cu-DOTA-TNYL-RAW in PC-3M tumors than in A549
tumors (0.84 %ID/g vs. 0.44 %ID/g, SD 5 0.09 and 0.09, respectively, P<0.000015).
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Figure 6B shows the biodistribution results of the mice bearing CT-26 tumor at 4 h post
injection of

64

Cu-DOTA-TNYL-RAW. The tumor The tumor-to-muscle ratio was

reduced 56.7% in CT-26 tumors at 4 h and 47.6% in PC-3M tumors at 24 h after coinjected

64

Cu-DOTA-TNYL-RAW with cold TNYL-RAW peptide compared with

injection of 64Cu-DOTA-TNYL-RAW only (Fig. 6C).

Figure 6A. Biodistribution of 64Cu-DOTA-TNYL-RAW in mice bearing PC-3M and
A549 tumors at 24 h after injection. Data are presented as %ID/g and are expressed as
mean±SD (n =4). (Reprinted with permission of (90))
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Figure 6B. Biodistribution of 64Cu-DOTA-TNYL-RAW in mice bearing CT-26 tumors
at 4 h after injection. Data are presented as %ID/g and are expressed as mean±SD (n
=4). (Reprinted with permission of (90))

Figure 6C. Tumor-to-muscle-uptake ratio in mice bearing CT-26 or PC-3M tumors. In
blocking group, mice were co-injected 64Cu-DOTA-TNYL-RAW (7.4 MBq [200 µCi])
with cold TNYL-RAW peptide (20 µg/mouse). Data are presented as mean±SD (n=6).
(Reprinted with permission of (90))

1.7 Immunofluorescence study on tumor sections
49

Immunofluorescence staining confirmed the expression of EphB4 on the CT26 and
PC-3M tumors, but there was no expression of EphB4 receptor on A549 tumor cells.
The ex vivo immunofluorescence results was similar to the pattern of in vitro binding
study.

Figure 7. Immunofluorescence analysis of EphB4 expression in CT26, PC-3M, and
A549 tumor sections excised after the imaging studies. Rabbit anti-human EphB4
antibody and goat anti-rabbit antibody conjugated with Alexa Flour 488 were used.
Bar=100 µm. (Reprinted with permission of (90))
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2. Evaluate 64Cu- and Cy5.5-labeled TNYL-RAW peptides for dual PET/optical
imaging of EphB4 receptors in orthotopic glioma models
2.1 Synthetic scheme of peptide Cy5.5-TNYL-RAW and Cy5.5-TNYL-RAWKDOTA
The peptide synthesis and introduction of Cy5.5 were carried out on solid phase
(Figure 8A). For synthesis of Cy5.5-TNYL-RAW-DOTA, the DOTA was introduced in
solution phase after cleavage of Cy5.5-TNYL-Raw peptide from the resin. After
cleavage and purification of those peptide by HPLC, they were characterized by
Electrospray ionization) mass spectrometry (ESI-MS). m/z [M+H]+ = 2604.0366;
calculated for Cy5.5-TNYL-RAW, C121H159N24O33S4: 2604.0384 and m/z [M+H]+ =
3175.3224; calculated for Cy5.5-TNYL-RAW-DOTA, C145H200N31O42S4: 3175.3350.
The radiochemical purity, defined as the ratio of the main product peak to all peaks, was
determined by HPLC to be >95%. The specific activity of Cy5.5-TNYL-RAWK-DOTA64

Cu used in the in vitro and in vivo experiments was typically 7.4-14.8 MBq/nmol (0.2-

0.4 Ci/µmol) at the end of synthesis. The structure details of Cy5.5-TNYL-RAW and
Cy5.5-TNYL-RAW –DOTA were shown in Fig 8B and 8C.
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Figure 8A. Synthetic scheme of peptide Cy5.5
Cy5.5-TNYL-RAW and Cy5.5-TNYL
TNYL-RAWKDOTA

Figure 8B. Structure details of Cy5.5-TNYL-RAW
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Figure 8C. Structure details of and Cy5.5-TNYL-RAWK-DOTA
2.2 Binding Affinity of Cy5.5
Cy5.5-TNYL-RAW and Cy5.5-TNYL-RAWK-DOTA
DOTA
Figure 9 shows representative sensorgrams obtained from SPR analyses of TNYLTNYL
RAW (Figure 1A), DOTA-TNYL
TNYL-RAW (Figure 1A), Cy5.5-TNYL-RAW
RAW (Figure 8B),
Cy5.5-TNYL-RAWK-DOTA
DOTA (Figure 8C) and scrambled peptide, with fitting curves
obtained using a global 1:1 mass transfer model. The corresponding binding kinetics and
affinity data are summarized in Table 3. TNYL-RAW had a KD of 3.06 nM. Conjugation
of Cy5.5 to the N terminus
us and/or DOTA to the C terminus of the peptide didn’t
significantly change the KD value of original TNYL-RAW
RAW peptide (1.27 nM and 1.01
nM respectively).
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Figure 9. SPR sensorgrams of DOTA-TNYL-RAW, Cy5.5-TNYL-RAW, Cy5.5TNYL-RAWK-DOTA and Cy5.5-scrambled peptide on sensor chips coated with
EphB4. Peptides were injected as ten 2-fold-concentration series from 1.6 to 800 nM and
were analyzed in duplicate binding cycles. Data sets (shown in black) are overlaid with
curves fit to 1:1 mass transfer interaction model (red lines). Vertical axes in response
units represent binding of each peptide to immobilized EphB4.
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Analyte

kon [M-1S-1]

koff [s-1]

KD [M]

χ2

DOTA-TNYL-RAW

1.1×
×105

2.56×
×10-3

2.33-8

0.28

Cy5.5-TNYL-RAW

4.15×
×106

5.28×
×10-3

1.27-9

4.37

DOTA-TNYL-

1.86×
×106

1.87×
×10-3

1.01-9

5.67

4.26X105

1.3X10-3

3.06-9

0.155

RAWK-Cy5.5
TNYL-RAW

Table 3. Association, Dissociation Rates and KD of different TNYL-RAW peptides and
derivatives interacting with immobilized EphB4 receptors obtained from SPR Analysis.
2.3 Detection of brain tumor growth by luciferase imaging
10 days after U87-Luc and U251-Luc tumor cells implanted in nude mice brain,
Tumor burden as measured by luciferase activity was assessed using Xenogen IVIS-200
Optical in Vivo Imaging System. Figure 10 clearly showed the luciferase activity in the
brain area of the nude mice in both tumor models, and there is no other detectable signal
in spinal cord area, which confirmed that the tumors were successfully grown in the.
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U87

U251

Figure 10. Representative Lucifease imaging of U251 and U87 glioblastoma on
orthotopic mice. Figure 10 shows luciferase signal of U251 and U87 10 days after tail
vein injection of luciferin.
2.4 Optical Imaging of U251 and U87 tumors in the brain
Figure 11A showed Cy5.5 optical imaging of U251 and U87 tumor in the brain. 24
hours after tail vein injection of Cy5.5-TNYL-RAW-DOTA, U87 or U251 tumor
implanted in nude mice brain was clearly visualized. To confirm the specific uptake of
Cy5.5-TNYL-RAW-DOTA to tumor, Cy5.5 conjugated scrambled peptide was used. In
figure 11B, U87 tumors in the brain of nude mice were clearly seen on optical imaging
at 1 h, 4 h and 24 h time point after tail vein injection of Cy5.5-TNYL-RAW-DOTA, but
there was little signal being detected in the nude mice brain after tail vein injection of
Cy5.5-scramble peptide at same time points.
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U87

U251

Figure 11A. Representative Cy5.5 optical imaging of U251 and U87 glioblastoma on
orthotopic mice. Cy5.5 near-infrared fluorescence optical imaging U251 and U87
tumors 24 hours after tail vein injection of 64Cu-Cy5.5-TNYLRAW-DOTA.
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Cy5.5-TNYL-RAW
C y5.5-Scram ble
Figure 11B. Representative near-infrared (NIR) fluorescence optical images of U87 after
tail vein injection of Cy5.5-TNYLRAW-DOTA or Cy5.5-scramble, imaging taken at
various time points. Figure 11B upper panel shows the NIR optical imaging of U87
tumors at 1h, 4h and 24 hours after tail vein injection of Cy5.5-TNYLRAW-DOTA.
Figure 10B lower panel shows the NIR optical imaging of U87 tumors at 1h, 4h and 24
hours after tail vein injection of Cy5.5-scramble peptides.
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2.5 Ex vivo analysis of the fluorescence signal intensities of dissected tissues
Figure 12A and 12B shows the biodistribution of Cy5.5-TNYL-RAW-DOTA or
Cy5.5-scramble-DOTA in mice bearing U87 tumors by ex vivo analysis of the
fluorescence signal intensities of dissected tissues. High fluorescence activity was found
in mice liver, kidney, stomach and intestine. Compared with fluorescence densities in
two groups at different time points, it clearly showed that U87 tumor has significantly
higher uptake of Cy5.5-TNYL-RAW-DOTA than that of Cy5.5-scramble-DOTA did.
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Cy5.5-TNYL-RAW
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Figure 12A. Representative near-infrared (NIR) fluorescence optical images of various
tissues obtained from the mouse at the end of the imaging sessions. Images were taken at
1h, 4h and 24 hours after i.v. injection of 64Cu-Cy5.5-TNYL-RAW-DOTA or 64CuCy5.5-scramble peptides.
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Cy5.5-TNYL-RAW

Cy5.5-scramble

Fig 12B. Biodistribution at 24h after i.v. injection of different peptides, obtained using
the fluorescence intensity measurement method, plotted as photon flux per gram of
tissue. All data are expressed as mean ±standard deviation (n=4).
2.6 Nuclear Imaging of tumors in the brain
Figure 13A shows small-animal PET/CT of both coronal and transverse slices that
contain U87 tumor. Tumors were clearly visualized at 1 and 24 h after tail vein injection
64

Cu-Cy5.5-TNYLRAW-DOTA. Figure 13B compares small-animal PET/CT images

obtained in the presence and absence of a large excess of cold Cy5.5-TNYLRAW (50
µg/mouse) at 1h and 24h after radiotracer injection in U251 tumor bearing mice. AT 1h
and 24 h after injection of radiotracer, the U251 tumors were clearly visualized
compared with barely detectable signal in blocking group. In U251 tumor models, the
co-administration of cold Cy5.5-TNYL-RAW-DOTA caused a 57% reduction in the

61

ratio of

64

Cu-Cy5.5-TNYLRAW-DOTA accumulations in tumors versus normal brain

based on tumor voxel intensity calculation from PET/CT image (Figure 13C).

U87
Transverse Plane

Coronal Plane

T

T

1h

T

T

24h

Figure 13A. Micro PET/CT images of mice bearing a U87 after intravenous
administration of 64Cu-labeled Cy5.5-TNYL-RAW-DOTA. The mice bearing a U87
tumortumor received 64Cu-labeled Cy5.5-TNYL-RAW-DOTA.
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U251
64Cu-Cy5.5-TNYL-RAW-DOTA

T Block
T

T
1h

T

T

24 h

Figure 13B. Micro PET/CT images of mice bearing a U251 after intravenous
administration of 64Cu-labeled Cy5.5-TNYL-RAW-DOTA. The mice bearing a U251
tumor received 64Cu-labeled Cy5.5-TNYL-RAW-DOTA or excess amount of cold
Cy5.5-TNYL-RAW-DOTA peptide as blocking group.
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*

64Cu-Cy5.5-TNYL-RAW-DOTA

Block

Figure 13C. Compared tumor voxel intensity / normal brain voxel intensity between
64
Cu-labeled Cy5.5-TNYL-RAW-DOTA and blocking group based on calculation from
an irregular 3-dimensional region of interest (ROI) manually drawn corresponding to
PET images. * Indicates p value <0.05
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Figure 13 D. Representative autoradiograph, fluorescence and H&E staining images of
excised brain tissue containing U251 tumors.
2.7 Immunohistochemistry
Figure 14 shows the immunofluorescence results of the expression of EphB4,
binding site of Cy5.5 labeled TNYL-RAW peptide on mice brain section containing
implanted tumor. In figure 14 upper panel, expression of EphB4 (green color) was
detected on both U251 tumor cells and tumor associated blood vessel (red color CD31
staining). The binding of

64

Cu-Cy5.5-TNYL-RAW-DOTA was also correlated with

EphB4 expression on tumor section, which was also detected on both tumor cells and
tumor associated vessels. From figure 14 lower panels, the expression of EphB4 was
only detected on tumor-associated blood vessel but not on tumor cells, which was also
corresponding to 64Cu-Cy5.5-TNYL-RAW-DOTA binding site on tissue sections.
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CD31

EphB4 (receptor)

Cy5.5-TNYL

DAPI/CD31/EphB4/TNYL-Cy5.5

U251

U87

Figure 14. Fluorescence microscopy of mice brains including implanted U87 or U251
tumors excised after imaging studies. The mice bearing a U251 or U87 tumor were
injected intravenously with 64Cu-labeled Cy5.5-TNYL-RAW-DOTA peptides. Signal
from Cy5.5-loaded TNYL-RAW-DOTA was pseudocolored purple. EphB4 (green) was
stained with rabbit anti-human EphB4 antibody and Alexa Flour 488-conjugated goat
anti-rabbit immunoglobulin. CD31 (red), which is the marker of the endothelial cells of
tumor associated vessel were stained with rat anti-mouse CD 31 antibody and Alexa
flour 594-conjugagted donkey anti-rat antibody. Cell nuclei were counterstained with
DAPI (blue). Bar=100 µm.
3. To develop and evaluate EphB4 specific peptide conjugated HAuNS for
photothermal ablation therapy of colon cancer in vitro and vivo
3. 1 Synthesis and Characterization of TNYL-PEG-HAuNS
The structure of TNYL-PEG-SATA peptide was shown in Figure 15 A. The
reaction scheme of the conjugation of TNYL-PEG-SATA peptide the surface of HAuNS
is shown in Figure 15B. Figure15C is the resonance absorbance of these different AuNS
particles. This data showed that there were no significant changes in the resonance
absorbance of HAuNS after conjugation with TNYL-PEGS-SATA or PEG-SH. The
absorbance peaks of different HAuNS solutions are still around at 800nm which is
suitable for phothothermal therapy at near infrared region. Calculation of the number of
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peptide per particle was based on the result of amino acid analysis from the core facility
in Baylor College of Medicine. Each particle has app
approximate
roximate 40 peptides coupling on
its surface. As confirmed by instant thin
thin-layer
layer chromatography, the radiolabeling purity
of TNYL-PEG-HAuNS
HAuNS was about 98% after purification by centrifuge.

Figure 15A. structure details of TNYL-PEGS-SATA

Figure 15B. Reaction scheme for the conjugation of TNYL
TNYL-PEG-SATA
SATA to HAuNS.
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Figure 15C. The resonance absorbance of these different HAuNS particles (AuNS,
PEG-HAuNS, TNYL-PEG-HAuNS)
Colon and prostate cancer model for photothermal therapy
3.2 Fluorescence and dark field microscope
EphB4 receptors are overexpressed in PC-3M and CT-26 cells [38]. Figure 16 shows
the dark field images of PC-3M human prostate cancer cells and CT26 murine colon
cancer cells incubated with TNYL-PEG-HAuNS. The uptake of TNYL-PEG-HAuNS
was high in EphB4-positive PC-3M and CT-26 cells, while there was very low uptake of
PEG-HAuNS in both cells, suggesting that the high uptake of the TNYL-PEG-HAuNS
was mediated through EphB4. Moreover, the specific uptake of TNYL-PEG-HAuNS in
PC-3M and CT-26 cells could be efficiently blocked by excessive amount of TNYLPEG-SATA peptides
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Figure 16. Fluorescence microphotographs (dark field) and radioactive uptake study of
EphB4-positive PC-3M and CT-26 cancer cells after incubation with TNYL-PEGHAuNS or PEG-HAuNS. Representative fluorescence and dark field microphotographic
images. In right panel, PC-3M cells were incubated with TNYL-PEG-HAuNS (left
upper) for 2 h; PC-3M cells were incubated with PEG-HAuNS (left middle) for 2 h; PC3M cells were co-incubated with TNYL-PGL-HAuNS and excess amount of TNYLPEG (Left lower) for 2 h. In left panel, CT-26 cells were incubated with TNYL-PEGHAuNS (left upper) for 2 h; CT-26 cells were incubated with PEG-HAuNS (left middle)
for 2 h; CT-26 cells were co-incubated with TNYL-PGL-HAuNS and excess amount of
TNYL-PEG (Left lower) for 2 h. Signal from dark field is pseudocolored green. Cell
nuclei were counterstained with DAPI (blue). Scale bar=50 µm.
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3.3 In vitro radioisotope binding assay
Cell uptake of TNYL-PEG-HAuNS was also evaluated by the radioactivity count
method, and the result was consistent with the results obtained by dark field fluorescence
microscopy. PC-3M cells and CT-26 showed significantly higher uptake of 64Cu-labeled
TNYL-PEG-HAuNS than the uptake of

64

Cu-labeled PEG-HAuNS (Figure 17). The

above cell binding results confirmed that TNYL-PEG-HAuNS can specifically bind to
EphB4 positive cancer cells.

Figure 17. Radioactive uptake study of cells incubated with 64Cu labeled TNYL-PEGHAuNS or PEG-HAuNS. PC-3M cells (left) were incubated with 64Cu labeled TNYLPEG-HAuNS (dark gray) or TNYL-HAuNS (light gray) for 2 h; CT-26 cell (right) were
incubated with 64Cu labeled TNYL-PEG-HAuNS (dark gray) or TNYL-HAuNS (light
gray) for 2 h. The data were expressed as cpm/µg protein in cell pellet over cpm/µg
medium and presented as mean ± standard deviation (n=5). * Indicates statistically
significance with P<0.01
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3.4 In vitro photothermal ablation of cancer cells
To compare the photothermal effect of TNYL-PEG-HAuNS with original HAuNS
and PEG-HAuNS, above three nanoparticle solutions were exposed to an 8 W/cm2 near
infrared-region laser respectively. The temperature of all solutions was increased from
27 ºC to 75 ºC at the concentration of 4x1011 particles/mL. There was no significant
difference in the changes of temperature among these nanoparticles (Figure 18). These
data suggested that HAuNS still can be an efficient photothermal coupling agent after
conjugation with TNYL–PEG-SATA or PEG-SH. Figure 18 and 19 show that most of
PC3-M and CT-26 cells treated with TNYL-PEG-HAuNS plus NIR laser irradiation (40
W/cm2 for 5 min) were not stained by calcein AM dye but stained for Eth-D1, which
suggested that majority of cells were dead after NIR laser treatment. In contrast, cell
viability has no changes after treatment of PEG-HAuNS plus laser, and laser only. The
photothermal killing ability of TNYL-PEG-HAuNS was significantly abolished after
adding excess amount of TNYL-PEG-SATA.
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Figure 18. Heating
eating of aqueous TNYL
TNYL-PEG-HAuNS, PEG-HAuNS
HAuNS or HAuNS solutions
exposed to NIR light centered at 808 nm at 8 W/cm2.
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Figure 19. CT-26 cells viability after various treatments, most of cells were dead after
treatment with TNYL-PEG-HAuNS plus NIR laser. Live cells were stained with calcein
AM and dead cells were stained for Eth-D1. Scale bar=100 µm.
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Figure 20. PC-3M cells viability after various treatments. Most of cells were dead after
treatment with TNYL-PEG-HAuNS plus NIR laser. Live cells were stained with calcein
AM and dead cells were stained for Eth-D1. Scale bar, 100 µm.
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3.5 Micro-PET Imaging
Figure 21 showed the micro-PET images of the mice bearing CT-26 tumors
acquired at 1, 6, and 24 h after intravenous injection of
64

64

Cu-TNYL-PEG-HAuNS or

Cu- PEG-HAuNS. Micro-PET images revealed that the uptake of

64

Cu-TNYL-PEG-

HAuNS in the tumor was gradually accumulated from 1 h to 24 h. The tumor was
clearly visualized at 24 h after the injection of

64

Cu-TNYL-PEG-HAuNS. There were

fewer signals detected in the tumors of mice injected with 64Cu- PEG-HAuNS.

Figure 21. Micro PET imaging of mice bearing a CT-26 tumor after intravenous
injection of 64Cu labeled TNYL-PEG-HAuNS or TNYL-HAuNS. The mice bearing a
CT-26 tumor were administration of 64Cu labeled TNYL-PEG-HAuNS or PEG-HAuNS.
Representative micro PET images at 1h, 6h, and 24h after tail vein i.v. injection of 64Cu
labeled TNYL-PEG-HAuNS and Representative micro PET images at 1h, 6h, and 24h
after tail vein i.v. injection of 64Cu labeled PEG-HAuNS.
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3.6 In vivo biodistribution
The biodistribution data described in Figure 22 are consistent with the micro-PET
imaging results. At 24 h after injection, uptake of

64

ID/g) in CT-26 tumors was significantly higher than

Cu-TNYL-PEG-HAuNS (4.92%

64

Cu-PEG-HAuNS (1.49% ID/g)

(P<0.001). The ratio of tumor-to-muscle in the mice injected with

64

Cu-TNYL-PEG-

HAuNS (25.9) was four times higher than that in the mice injected with

64

Cu-PEG-

HAuNS (6.2). The ratio of tumor-to-blood in the mice injected with 64Cu-TNYL-PEGHAuNS (2.94) was 1.5 times higher than that in the mice injected with

64

Cu-PEG-

HAuNS (2.0)

Figure 22. In vivo biodistribution and tumor uptake of 64Cu labeled TNYL-PEGHAuNS or PEG-HAuNS in mice bearing a CT-26 tumor, 24 h after intravenous injection.
The mice bearing CT-26 tumor received 64Cu labeled TNYL-PEG-HAuNS light (light
gray), or 64Cu labeled PEG-HAuNS (dark gray).

76

3.7 In Vivo Photothermal Therapy
Mice bearing CT-26 tumor were treated with TNYL-PEG-HAuNS, PEG-HAuNS
(2x1012 per mouse, 200 µL) or saline (as control 200 µL). 24 h after injection, the tumors
were treated with NIR irradiation. The skin at the tumor sites in mice that received
intravenous injection of TNYL-PEG-HAuNS turned brownish, indicating tissue burns
caused by the local photothermal effect. In contrast, there were less color changes
(turned into a little white) in the skin of mice treated with PEG-HAuNS plus laser. There
was no color changes in the skin of mice treated with saline plus NIR irradiation, or NIR
laser alone (Figure. 23A). Histological examination of tissue slides cut from tumor
confirmed that the intravenous injection of TNYL-PEG-HAuNS followed by laser
treatment caused significantly greater thermonecrotic response than PEG-HAuNS plus
laser treatment, saline plus laser treatment, or saline only did (Figure. 23B). In the mice
treated with TNYL-PEG-HAuNS plus the laser, (Figures 23B and C), majority of tissues
(82% of tissues) were necrotized, prominent features of thermonecrosis were found, such
as karyolysis, cytoplasmic acidophilia, and corruption and degradation of the
extracellular matrix of the tumor. Only a small fraction of the necrotic tissues (18.8% of
tissues) was found in the tumor treated with PEG-HAuNS plus NIR laser (Figure 24)
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Figure 23. AuNS nanoparticles can induce photothermal killing of CT-26 tumors in
vivo. (A) Photographs of tumor-bearing mice before and at after NIR laser irradiation
(3W/cm2 at 808 nm for 5 min). (B) Representative microphotographs of tumors removed
24 h after NIR laser treatment. The tissues were cryosectioned into 5 µm slices and
stained with hematoxylin/eosin. Scale Bar, 500µm (C) Magnification of necrosis portion
of tumor after laser treatment (red color) and normal part of tumor tissue after laser
treatment (green color), Scale Bar=50µm.
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Figure 24. The necrotic area as a percentage of the tumor is shown in the bar graph. * P
< 0.005 (n = 4).

4. Preliminary study to evaluate EphB4 specific peptide conjugated HAuNS for
photothermal ablation therapy of ovarian cancer in vitro and vivo
4.1 Expression of EphB4 receptors on Hey A8-Luc
In order to confirm the expression of EphB4 receptor in the Hey A8-Luc ovarian
cancer cells, in vitro immunofluorescence study was performed. Figure 25 shows that
EphB4 is expressed on the Hey A8-Luc cells compared with IgG control group.
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Figure 25. Fluorescence photomicrographs of HeyA8-Luc cells stained with rabbit antihuman EphB4 1st antibody (1:100 dilution) and goat anti-rabbit 2nd antibody conjugated
with Alexa Fluor 488 (1:500 dilution). Upper panel shows cells incubated with antihuman EphB4 1st antibody and goat anti-rabbit 2nd antibody. Lower panel shows the
results of IgG control group.

4.2 In vitro photothermal ablation of Hey-A8 cancer cells
Figure 26 shows that most of Hey A8-Luc cells treated with TNYL-PEG-HAuNS
plus NIR laser irradiation (40 W/cm2 for 5 min) were not stained by calcein AM dye but
stained for Eth-D1, which suggested that majority of cells were dead after NIR laser
treatment. In contrast, cell viability has no changes after treatment of PEG-HAuNS plus
laser, and laser only. The photothermal killing ability of TNYL-PEG-HAuNS was
significantly abolished after adding excess amount of TNYL-PEG-SATA.
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Figure 26. Hey A8-Luc cells viability after various treatments. Most of cells were dead
after treatment with TNYL-PEG-HAuNS plus NIR laser. Live cells were stained with
calcein AM and dead cells were stained for Eth-D1. Scale bar, 100 µm.
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4.3 Detection of Hey-A8 tumor growth by luciferase imaging
14 days after Hey-A8-Luc tumor cells intraperitoneally implanted in nude mice,
Tumor burden as measured by luciferase activity was assessed using Xenogen IVIS-200
Optical in Vivo Imaging System. Figure 27 clearly showed the luciferase activity in the
belly area of the nude mice in Hey-A8 tumor models, which confirmed that the tumors
were successfully grown in the nude mice.

Figure 27. Representative Lucifease images of Hey-A8 tumor on intraperitoneal nude
mice model. Figure 10 shows luciferase signal of Hey-A8-Luc 14 days after tail vein
injection of luciferin.
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4.4 In vivo biodistribution on intraperitoneal Hey-A8 ovarian tumor model
At 24 h after injection, uptake of 64Cu-TNYL-PEG-HAuNS (4.67% ID/g) in Hey-A8
tumors was higher than

64

Cu-PEG-HAuNS (3.4% ID/g) (P<0.005). The ratio of tumor-

to-muscle in the mice injected with 64Cu-TNYL-PEG-HAuNS was 11.67 compared with
the mice injected with 64Cu-PEG-HAuNS (6.9). The ratio of tumor-to-blood in the mice
injected with

64

Cu-TNYL-PEG-HAuNS (1.5) was almost the same as that in the mice

injected with 64Cu-PEG-HAuNS (1.8).

Figure 28. In vivo biodistribution and tumor uptake of 64Cu labeled TNYL-PEGHAuNS or PEG-HAuNS in mice bearing Hey-A8-Luc (intraperitoneal) tumor, 24 h after
intravenous injection. The mice bearing Hey-A8-Luc tumor received 64Cu labeled
TNYL-PEG-HAuNS light (red), or 64Cu labeled PEG-HAuNS (blue).

4.5 In Vivo Photothermal Therapy in Hey-A8 ovarian cancer model
Mice bearing Hey-A8 tumor were treated with PEG-HAuNS (2x1012 per mouse, 200
µL) or saline (as control 200 µL). 24 h after injection, the tumors were treated with NIR
irradiation. The tumor received intravenous injection of PEG-HAuNS turned brownish,
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indicating tissue burns caused by the local photothermal effect. There were no color
changes in the tumor treated with saline plus NIR irradiation. The tumor treated with
PEG-HAuNS plus the laser, (Figure 29), majority of tissues were necrotized, prominent
features of thermonecrosis were found, such as karyolysis, cytoplasmic acidophilia, and
corruption and degradation of the extracellular matrix of the tumor. The structure of
intestine surrounding tumors that were received photothermal treatment is intact, no
significant thermal damage or necrosis was found on tissue slides.

Figure 29. AuNS nanoparticles can induce photothermal killing of Hey-A8 tumors in
vivo. (B) Representative microphotographs of tumor and intestine removed 24 h after
NIR laser treatment. The tissues were cryosectioned into 5 µm slices and stained with
hematoxylin/eosin. Scale Bar, 50µm
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DISCUSSION
In current study, we successfully developed EphB4 specific TNYL-RAW peptide
and found that tail vein injection of the 64Cu labeled TNYL-RAW peptide allowed ready
visualization of EphB4 positive tumor in different nude mice xenograft models by
PET/CT. We also synthesized the dual-labeled

64

Cu-TNYL-RAW-Cy5.5 peptides and

evaluated the potential application of this peptide for micro PET/CT imaging and near
infrared optical imaging in orthotopic glioblastoma (U87 and U251) mice models.
Moreover, we synthesized EphB4 specific peptide TNYL-RAW conjugated hollow gold
nanoshell for targeted micro PET imaging and photothermal ablation of EphB4overexpressing cancer cells in vitro and vivo.
EphB4 receptor has attracted a lot of interest in cancer imaging recently due to
widespread overexpression of EphB4 receptor in lots of different tumors (93). It is
possible to develop noninvasive imaging techniques to early diagnosis of patients with
high expression of EphB4 receptors in their tumors or monitor the chemotherapy
response of the tumors by using EphB4 receptor specific targeting agent. For this
purpose, we successfully synthesized and radiolabeled (64Cu) the EphB4 specific peptide
TNYL-RAW for PET imaging based on the previous paper published peptide sequence
(50).
Based on the SPR analysis, the KD value of TNYL-RAW peptide was 3.09 nM, which
is similar to the previous literature published (KD, 1–2 nM) (50). The slow dissociation
rate of the TNYL-RAW peptide (~1.3x10-3 [s-1] strongly indicated that this peptide is
suitable for in vivo molecular imaging applications due to its simple binding affinity. It
has been reported that the stability of binding complex with EphB4 was not significantly
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affected by modifying the N terminus of the peptide (94). However, based on our SPR
analysis, it is interesting to find out that there was an 8-fold reduction in KD value of the
TNYL-RAW when the N terminus of TNYL-RAW was modified by introducing the
radiometal chelator DOTA. But the coupling of Cu2+ to the DOTA-TNYL-RAW peptide
can restore the binding affinity of TNYLRAW to 1.89 nM (Table 1). Therefore, the
subtle modification of N terminus of TNYL-RAW peptide can still affect the binding
affinity of the TNYL-RAW to EphB4 receptors. Because there was no significant
interaction between the scramble peptide and EphB4 receptors, we concluded that this
TNYL-RAW binding to EphB4 in vitro is sequence specific. In the literature, there has
been reported that EphB4 receptors are overexpressed in most of colon cancer and
prostate cancer cell lines (38, 95, 96). The CT26 (mouse colon cancer cell lines) and PC3M (human prostate cancer cell lines) cells used in our study has been confirmed
positive for EphB4 expression (Figure 3) by immunofluorescence study. FITC labeled
TNYL-RAW peptide exhibits high affinity and specific binding to EphB4 receptor in
vitro binding study. The similar binding pattern to EphB4 positive cancer cells was also
found in the results of

64

Cu-DOTA-TNYL-RAW uptake study (Fig. 3 and 4). The

specific binding of peptide to EphB4 receptor was confirmed by in vitro blocking study.
All above results indicated that 64Cu- DOTA-TNYL-RAW peptide is a suitable probe for
noninvasive imaging of EPhB4 receptors.
The uptake of

64

Cu- DOTA-TNYL-RAW was significantly high in EphB4 positive

PC-3M and CT-26 tumor xenografts in nude mice by in vivo micro PET/CT studies. In
contrast, the radiotracer showed very low uptake in EphB4 negative A549 tumors at all
time points examined (Fig. 5). To further confirm the expression status of EphB4 in
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different tumors, ex vivo immunohistostaining of tumor xenografts sections was
performed. The results showed that high expression level of EphB4 receptors was
observed in both CT26 and PC-3M tumors but not in A549 tumors. From the micro
PET/CT images, the radioactivity signal of

64

Cu-DOTA-TNYL-RAW in CT26 tumors

was significantly reduced after 4h post i.v. injection of radiotracer. In contrast, the signal
of radioactivity reached highest in PC-3M tumors at 24 h post injection (Fig. 24).
Because the relatively slow dissociation rate of peptide-EphB4 receptor complex, the
major determinant of the difference in the signal intensity at various time points between
those two tumors are the expression levels of EphB4 receptors on these two tumors.
However, this different radiotracer retention time in tumor tissues between CT26 and
PC-3M tumor mice models could also be explained by the difference in the degradation
of

64

Cu-DOTA-TNYL-RAW

peptide–based

radiotracer

in

different

tumor

microenvironments. It is very critical for maintaining the molecular integrity of the
radioactive peptides in vivo condition in order to circulation in blood for the purpose of
biodistribution and imaging studies. We tested the stability of 64Cu-DOTATNYL- RAW
DMEM with 10% FBS and in mouse serum. We found out that it was stable in DMEM
with 10% FBS for at least 24 h and in mouse serum for up to 2 h (Chiyi Xiong, et al.
unpublished data). The slow degradation of peptide was observed in mouse serum after 2
h incubation. The above slow metabolic degradation of the radiolabeled peptide could
be explained by the proteolysis of linear peptides by plasma peptidases present in mouse
serum (97). In order to improve the stability of the peptide, we can introduce D-amino
acid into the peptide sequence or cyclization of the peptide to make it more resistant to
enzymatic degradation (98, 99). The studies of improving in vivo stability of TNYL-
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RAW are in progress. Based on our stability data and in vivo PET/CT imaging results,
the stability of our peptides is sufficient for in vivo applications of tumor imaging and
biodistribution study.
In order to confirm the specificity uptake of

64

Cu- DOTA-TNYL-RAW in EphB4

positive tumors in vivo, blocking studies were performed by co-administration of the
radiolabeled peptides with excess amount of nonradioactive (cold) TNYL-RAW peptide.
There were significant reductions in the uptake of

64

Cu- DOTA-TNYL-RAW in both

CT26 and PC-3M tumors with co-injection of radiotracer with excess amount of cold
TNYL-RAW (Figure 5B) from micro PET/CT image results. Quantitative analysis of
and comparison of radioactive uptake of

64

Cu- DOTA-TNYL-RAW in different tumor

tissues based on the ROI manually drawn from the micro PET/CT images showed that
77% and 81% reduction in

64

Cu-DOTA-TNYL-RAW uptake in CT-26 and PC-3M

tumors at 4h or 24h respectively (Fig. 5B). The low uptake of

64

Cu- DOTA-TNYL-

RAW (Figure. 5A) in EphB4 negative expression A549 tumors together with all above
results supported conclusion that the specific uptake of

64

Cu- DOTA-TNYL-RAW in

EphB4 positive colon and prostate cancer xenografts in nude mice models was mediated
by EphB4 receptors. The biodistributions of

64

Cu-DOTA-TNYL-RAW in different

tumor models obtained by both noninvasive PET/CT calculated from ROI and by in vivo
tissue sampling indicated that the major organs for uptake and clearance of this
radiopharmaceutical were in liver and the kidney. It was well known that the major
organ for clearance of hydrophobic peptides is in liver (100). The high level of uptake of
64

Cu-DOTA-TNYL-RAW in liver could be attributed to compositions of the

hydrophobic amino acids (Asn, Ile, Leu, Phe, Pro, Ala, Trp) in TNYL-RAW peptides.
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Also the significant uptake of the radiotracers in the nude mice kidneys was due to the
degradation of the peptide by lysosome within renal cells (101). Therefore, it is
important for us to optimize pharmacokinetics and in vivo stability of peptides for in vivo
imaging applications.
Glioblastoma is the most malignant primary brain tumor that is resistant to most of
common drug therapies. The frequent recurrence of this tumor is due to its infiltration
into surrounding normal brain tissue and difficulty in complete resection of the tumors
(102, 103). It is important to develop diagnostic imaging agent to monitor tumor growth
in the brain and evaluate tumor responses to therapeutic drugs. Recently, lots of optical
imaging using near infrared fluorescent dye labeled tumor-specific molecules has been
successfully applied to imaging glioma in preclinical animal models based on the
overexpression of specific marker on glioma (104-106). The characteristics of near
infrared fluorescence (NIR) such as long wavelength (650–900 nm), lower light
absorbance and scattering, and reduced autofluorescence of normal tissues make it great
potential in clinical imaging application (107). Several recent studies have demonstrated
that using fluorescence imaging to improve radical resection of GBM during surgery
(108-110). Meanwhile, nuclear imaging has high detection sensitivity ability, which
makes it especially suitable for tracking radiotracers used in in vivo molecular imaging.
So, it is highly desirable to develop an imaging probe combining a radioisotope and a
near-infrared fluorescent dye for dual nuclear and optical imaging of glioma.
Overexpression of EphB4 receptors has been reported in a number of tumors. Up to now,
there are few papers describing the applications of EphB4 as target for cancer imaging
(35, 36). In high-grade glioma, EphB4 are expressed at high levels in both tumor cells
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and blood vessels16. In current study, we developed dual-labeled EphB4 specific TNYLRAW peptides for visualization of glioblasotomas with micro PET/CT and near-infrared
fluorescence imaging on orthotopic mice model.
SPR analysis showed that the KD values of Cy5.5-TNYL-RAW and Cy5.5-TNYLRAW-DOta are around 1nM which have no significant changes compared with the value
of original TNYL-RAW peptide (3.07 nM). The high binding affinity of the dual labeled
EphB4 specific peptide to EphB4 receptor in vivtro makes it suitable for in vivo
molecular imaging application. For monitor intracranial tumor growth in nude mice, we
made the stable cell lines that express the luciferase gene. Ten days post injection of
tumors in the mice brains, the detectable luciferase signal has been visualized on
Xenogen imaging system which corresponded to the tumor growth in the mice brain.
Near infrared fluorescence imaging studies revealed that Cy5.5-TNYL-RAW-DOTA has
significant higher uptake in U251 and u87 tumors in orthotopic nude mice model. To
confirm the specificity of uptake of EphB4 targeted peptide in tumors, Cy5.5 labeled
scramble peptides have been used. From various time points of optical imaging, it
clearly showed that there was low uptake of scramble peptides uptake in U87 tumors
compared with that of Cy5.5-TNYL-RAW-DOTA peptides, which indicated that this
high uptake of EphB4 peptides into tumors was mediated through EphB4 receptor
(Figure 11B). The biodistribution data showed the same result as fluorescence optical
imaging based on ex vivo analysis of the fluorescence signal intensities of dissected
tissues.

High fluorescence activity was found in mice liver, kidney, stomach and

intestine. Compared with fluorescence densities in two groups at different time points, it
clearly showed that U87 tumor has significantly higher uptake of Cy5.5-TNYL-RAW-
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DOTA than that of Cy5.5-scramble-DOTA (Figures 12A and 12B). It is interesting to
notice that the accumulation of Cy5.5-TNYL-RAW-DOTA was lower in liver than that
in kidney, but the uptake of

64

Cu-TNYL-RAW was similar in both kidney and liver in

previous results. This phenomenon maybe due to the underestimation of the fluorescence
signal obtained from liver. Previous paper published in our lab (111) demonstrated that
ex vivo analysis fluorescence intensity may have underestimated the uptake of
nanoparticles or compounds in organs with high blood perfusion. Because estimation of
uptake of compounds in tissues based on fluorescence intensity is less accurate the
radioactivity count method, our above data suggested that the biodistribution data should
be corrected in different organs when fluorescence method is used.
Micro PET/CT images revealed significant high uptake of

64

Cu labeled Cy5.5-

TNYL-RAW-DOTA peptides in U251 and in U87 tumor models. The intensity of
radioisotope labeled peptides was greatly reduced in U251 tumors after co-injection of
excess amount of cold peptide with the

64

Cu labeled Cy5.5-TNYL-RAW-DOTA

peptides (Figures 13A and 13B). Quantitative analysis of micro PET/CT imaging
revealed that In U251 tumor models, the co=administration of cold Cy5.5-TNYL-RAWDOTA caused a 57% reduction in the ratio of

64

Cu-Cy5.5-TNYLRAW-DOTA

accumulation in tumors versus normal brain, which demonstrated the specific uptake of
dual labeled TNYL-RAW-DOTA peptide in U251 tumor. Immunofluorescence
microscope study showed an interesting phenomenon. For U251 tumor model, Cy5.5
labeled peptides mainly bind to tumor cells and tumor associated vessels which both
express EphB4 receptor on their surface. In contrast, the Cy5.5 labeled peptides only
bind to tumor associated vessel that express EphB4 but not on tumor cells that is
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negative staining for the expression of EpHB4 (Figure 14). It has been reported that
EphB4 are overexprerssed on brain tumor cells and tumor associated vessels. This is the
first time we show here that the new developed dual-labeled EphB4-specific peptide
could be used as a non-invasive molecular imaging agent for PET/CT and optical
imaging of glioma owing to its ability to bind to EphB4-expressing angiogenic blood
vessels and/ or to EphB4-expressing tumor.
HAuNS have already shown the great potential in photothermal therapy of cancer
due to their unique characteristics such as small size (30-60 nm), spherical shape, and
hollow interior and strong tunable (520-950nm) absorption band (74). The further
application of the HAuNS to cancer therapy is to develop targeted delivery of
nanoparticles into tumors to minimize the thermal damage to surrounding normal tissues.
With this aim, we developed TNYL-conjugated HAuNS for selective photothermal
killing of EphB4 positive cancer cells. In current study, we successfully conjugate
EphB4 specific (TNTL-PEG) peptide and/or PEG-SH onto the surface of HAuNS
without significant changes of the properties of HAuNS. From resonance absorbance
curves, the absorption peak of the TNYL-PEG-HAuNS or PEG-HAuNS is still around
800nm compared with original HAuNs, which demonstrates that conjugation of peptides
onto the surface of HAuNS has no obvious effect on the plasma resonance property. The
temperature of nanoparticle solutions was increased from 27 ºC to 75 ºC at the
concentration of 4x1011 particles/mL after exposure to near infrared-region laser light.
The photothermal effect of these particles remains no changes after conjugation of
peptides. The amount of peptides on the surface of HAuNS will also affect the specific
binding affinity of HAuNS to EphB4 positive tumors. From our amino acid analysis of
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conjugated HAuNS, the number of peptides on the surface of HAuNS is around 40,
which will greatly increase the binding repertoire of original TNYL-PEG peptide. As
shown in Figures 16, TNYL-PEG-HAuNS but not PEG-HAuNS binds to EphB4
positive PC-3M and CT-26 cells. Moreover, the uptake of TNYL-PEG-HAuNS to CT26 or PC-3M cells could specifically be blocked by excess amount of free TNYL-PEG
peptides, indicating that TNYL-PEG-HAuNS was taken up by the PC-3M or CT-26 cells
through EphB4 receptor-mediated. After exposure CT-26, PC3-M or Hey-A8 cells
treated with TNYL-PEG-HAuNS or PEG-HAuNS to NIR laser at 40W/cm2 for 5 min,
almost majority of cancer cells treated with TNYL-PEG-HAuNS were destroyed after
exposure to laser, but this effect was not observed in cells exposed NIR laser alone or
PEG-HAuNS plus laser group. This photothermal killing effect was efficiently abolished
by the addition of excess amount of PEG-TNYL peptide into the reaction.
For in vivo active targeting nanoparticles to the tumor tissue, HAuNS must be capable
of extravasating into the tumor interstitial space. Our HAuNS with small size makes it
suitable for in vivo delivery to tumor site. The photothermal effect of HAuNS in vivo
depends on the number of particle actively taken up by the tumor. To quantify the
amount of nanopaticles specific delivery to EphB4 positive CT-26 tumors in vivo after
systematic administration of

64

Cu-TNYL-PEG-HAuNS or

64

Cu-PEG-HAuNS, micro-

PET and in vivo biodistribution experiments were performed. From Figure 21, it clearly
showed that the tumor was visualized at 1 hour after the injection and the signal was
strongest at 24 h post injection. But low signal in the tumors of mice injected with 64CuPEG-HAuNS was also observed, which suggested that non-specific uptake of HAuNS in
the tumor tissue. This nonspecific uptake phenomenon can be explained by the EPR
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(enhanced permeability and retention) effect. The EPR effect is the property by witch
that certain size of the molecules such as liposomes, nanoparticles and some
macromolecules can accumulate into the tumor tissue much more than they do in normal
tissues due to the pathophysiological changes of tumor vessels (extensive angiogenesis
defective vascular architecture, and greatly increased production of permeability
mediators) (112-115). The biodistribution study also showed the similar results to the
micro-PET imaging study. At 24 h after injection of radiolabeled nanoparticles, uptake
of

64

Cu-TNYL-PEG-HAuNS was significantly higher (4.92% ID/g) in CT-26 tumors

than that of 64Cu-PEG-HAuNS was. (1.49% ID/g) (p<0.001). The tumor-to-muscle ratio
was 6.2 in the mice injected of 64Cu-PEG-HAuNS, while it was 25.9 in the mice treated
with

64

Cu-TNYL-PEG-HAuNS. Also the The ratio of tumor-to-blood in the mice

injected with 64Cu-TNYL-PEG-HAuNS (2.94) was 1.5 times higher than that in the mice
injected with

64

Cu-PEG-HAuNS (2.0) (p<0.005). Taken together, all above data

demonstrate that TNYL-PEG-HAuNS can be specifically uptake into EphB4 positive
CT-26 tumors compared with control PEG-HAuNS. (Figure 22). In vivo photothermal
therapy study confirmed that tumor with intravenous injection of TNYL-PEG-HAuNS
plus laser treatment caused significantly greater thermonecrotic response than that of
mice treated with PEG-HAuNS plus laser treatment, saline plus laser treatment, or saline
only (Figs. 23B and 23C). In the mice treated with TNYL-PEG-HAuNS plus the laser,
(Figures 23B and C), majority of tissues (82% of tissues) were necrotized, prominent
features of thermonecrosis were found, such as karyolysis, cytoplasmic acidophilia, and
corruption and degradation of the extracellular matrix of the tumor. Only a small fraction
of the necrotic tissues (18.8% of tissues) was found in the tumor treated with PEG-
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HAuNS plus NIR laser (Figure 24). From histological results, we still can observe some
necrosis response in PEG-HAuNS plus laser treatment group, which also can be
explained by EPR effect witch corresponding to the result of micro-PET and
biodistribution data. Our current study clearly shows the selective killing tumor cells
after intravaneously injection of TNYL-PEG-HAuNS plus near infrared-region laser
light treatment. But the tumor model we choose here is subcutaneous tumor model
which may not reflect the real situation due to the local blood flow difference between
subcutaneous of the mouse skins and orthotropic sites.
Therefore, further studies will focus on the application of TNYL-PEG-HAuNS in
orthotropic tumor models for further investigation of their photothermal killing effect in
vivo. But the study of biodistribution of 64Cu-TNYL-PEG-HAuNS or 64Cu-PEG-HAuNS
on Hey-A8-Luc ovarian cancer intraperitoneal nude mice models showed that the uptake
of

64

Cu-TNYL-PEG-HAuNS was statistically higher (4.67% ID/g) in Hey-A8 tumors

than that of

64

Cu-PEG-HAuNS was (3.4% ID/g) (P<0.005). But the ratio of tumor-to-

blood in the mice injected with 64Cu-TNYL-PEG-HAuNS (1.5) was almost the same as
that in the mice injected with
different uptake of

64

64

Cu-PEG-HAuNS (1.8), which suggested that the

Cu-TNYL-PEG-HAuNS and

64

Cu-PEG-HAuNS in the Hey-A8

tumors may be due to the EPR effect. Although we didn’t get promising data from
orthotopic ovarian cancer models, it still provided us useful information. In clinical
situation, it is very difficult to treat metastatic spread of ovarian cancer in pelvic of
patients. Because we didn’t find good targeting effect of TNYL-PEG-HAuNS on HeyA8 nude mice model, we want to study the photothermal killing effect of PEG-HAuNS
on tumors after intraveneously injection of the nanoparticles due to the high uptake of
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the 64Cu-PEG-HAuNS (3.4%) in tumor. After treating the tumor with laser at 2W/cm 2,
the color of the tumor of the mice injected with PEG-HAuNS turned into brown color,
but there is no color change of the tumor with saline injected or with no treatment. H&E
staining results showed that majority of tissues were necrotized, prominent features of
thermonecrosis were found, such as karyolysis, cytoplasmic acidophilia, and corruption
and degradation of the extracellular matrix of the tumor. For saline control or no
treatment group, there was no thermonecrosis area in the tumor section. To check
whether the laser treatment will damage the local normal tissue surrounding the tumor,
the intestine tissues around the tumor were also taken out and cut into sections. We can
see that the structure of intestine was still intact and there is no photothermal damage to
the normal intestine tissues so far. It is still preliminary data for investigation of
photothermal effect on Hey-A8 intraperitoneal ovarian cancer model. In the future, we
need test this killing effect on more mice to collect data to figure out whether this local
photothermal effect will kill tumor cells but cause no or minimum damage to the tissue
surrounding it. Because we only tested our nanoparticles on one ovarian orthotopic
model, we still need check other orthotopic ovarian cancer models such as transgenic
mice models to further investigate the targeting effect of TNYL-PEG-HAuNS in vivo.
Though TNYL-RAW showed a great potential in the application of imaging tumor in
mice and cancer thermal therapy when conjugated with HAuNS, there is a still long way
to go before we apply it in clinical use. First, the slowly degradation of TNYL-RAW in
mouse serum indicates that the detection sensitivity will decrease after long time
circulation in the body. It is important to improve the stability of this peptide for its
clinical application. Introduction of D-amino acid or cyclization of peptide can make it
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more resistant to proteolytic degradation of peptide. Now we have already synthesized
the second generation of the peptides to optimize the stability of the peptide. Our SPR
analysis confirmed that introduction of D-amino acid into peptide sequence or
cyclization of the peptide did not significantly change the binding affinity of the peptide
to EphB4 receptor. In the future, we will evaluate its application in tumor imaging in
vivo by micro PET/CT or optical imaging. Secondly, it is obvious that the major organ
for the clearance of the peptide is liver. So it is highly desirable to modify the structure
of the peptide to reduce the liver clearance. Literature has been reported that pegylation
of the peptide can significantly reduce the liver nonspecific uptake of the peptide (116,
117). Synthesis and evaluation of the PEG conjugated TNYL-RAW in vivo PET/CT
imaging of tumor on nude mice is ongoing right now. Third, the tumor model we used in
this study for evaluate the peptide is subcurtaneously model and brain orthotopic models,
which is not the most ideal models for evaluation of peptide in vivo applications due to
difference in the local blood flow and microenviroment for tumor growth. There are lots
of transgenic mice tumor models available for prostate, colon and glioma cancers. We
will evaluate our peptide in these transgenic mice models for in vivo molecular imaging
applications. Conjugation of TNYL-RAW peptide onto the surface of the HAuNS makes
it suitable for targeting photothermal therapy. In this study we only use microscopic
study to evaluate necrotic response of photothermal therapy, which is not very accurate.
So it is highly desirable use other methods to evaluate tumor necrosis induced by
photothermal therapy. Our lab has developed

64

Cu-DOTA-hypericin for evaluation of

the tumor necrosis induced by photothermal therapy by PET/CT (118). Also

18

F-FDG

can also be used to monitor the changes of metabolic activity of the tumors by micro
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PET/CT (85).We can use above methods to monitor tumor response to the photothermal
therapy for EphB4 conjugated HAuNS. To monitor the tumor response to the
photothermal therapy, we can also monitor the tumor growth in long term after treatment
to see whether tumor growth can be inhibited by photothermal therapy. Because in
clinical settings, it is very difficult to remove all of the metastatic nodules in the pelvic
of ovarian cancer patients by surgery, it is very desirable to find alternative way to treat
this advanced stage disease to avoid using aggressive surgery treatment. Using
photothermal ablation therapy, the tumor can shrink and necrotized. So it is important
for us to study the photothermal effect of HAuNS on more ovarian cancer nude mice
models in future.
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CONCLUSIONS
In the current study, it is the first time to visualize tumor by in vivo noninvasive
micro PET/CT using EphB4 specific radiotracer

64

Cu- DOTA-TNYL-RAW. This

radiolabeled peptide could be used for early diagnosis of patients with high expression of
EphB4 receptors in their tumors or monitoring the chemotherapy response of the tumors.
To demonstrate the future potential of this radiotracer, it is important for us to evaluate it
in additional animal models and ex vivo human specimens. We also evaluated the
potential applications of

64

Cu and Cy5.5 dual labeled TNYL-RAW-DOTA peptides for

micro PET/CT imaging and near infrared optical imaging in orthotopic glioblastoma
mice model. µPET/CT and near-infrared optical imaging clearly showed the uptake of
the dual labeled TNYL-RAW peptide in both U251 and U87 tumors in the brains of
nude mice after intravenous injection. The specific uptake of dual labeled peptide in both
tumors was confirmed by blocking experiments. In U87 tumors, Cy5.5-labeled peptide
was found co-localized only with CD31- and EphB4-expressing tumor blood vessels.
Dual-labeled EphB4-specific peptide could be used as a non-invasive molecular imaging
agent for PET/CT and optical imaging of glioma owing to its ability to bind to EphB4expressing angiogenic blood vessels and to EphB4-expressing tumor. We developed the
EphB4 specific peptide conjugated HAuNS for micro PET imaging and photothermal
ablation of EphB4-overexpressing cancer cells in vitro and vivo. TNYL-PEG-HAuNS
targeted to EphB4 receptor have been shown to selectively bind to EphB4-positive
cancer cells (PC-3M and CT-26) and destroy these cells via a photothermal effect in
vitro. EphB4-positive CT-26 tumors were clearly visualized with

64

PEG-HAuNS. In vivo biodistribution study, up to 4.9.%ID/g of

64
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Cu-labeled TNYL-

Cu-labeled TNYL-

PEG-HAuNS was taken up by CT-26 tumor compared to TNYL-HAuNS. EphB4
targeted TNYL-PEG-HAuNS shows more photothermal killing effect on CT26 tumor
models than PEG-HAuNS do, which suggests that TNYL-PEG-HAuNS targeting to
EphB4 receptor may have future applications in photothermal ablation therapy in
clinical.

100

REFERENCES
1.

Hirai, H., Y. Maru, K. Hagiwara, J. Nishida, and F. Takaku. 1987. A novel
putative tyrosine kinase receptor encoded by the eph gene. Science 238:17171720.

2.

Maru, Y., H. Hirai, and F. Takaku. 1990. Overexpression confers an oncogenic
potential upon the eph gene. Oncogene 5:445-447.

3.

Bartley, T. D., R. W. Hunt, A. A. Welcher, W. J. Boyle, V. P. Parker, R. A.
Lindberg, H. S. Lu, A. M. Colombero, R. L. Elliott, B. A. Guthrie. 1994. B61 is a
ligand for the ECK receptor protein-tyrosine kinase. Nature 368:558-560.

4.

Pasquale, E. B. 2005. EPH receptor signalling casts a wide net on cell behaviour.
Nat Rev Mol Cell Bio 6:462-475.

5.

Gu, C., and S. Park. 2001. The EphA8 receptor regulates integrin activity
through p110gamma phosphatidylinositol-3 kinase in a tyrosine kinase activityindependent manner. Mol Cell Biol 21:4579-4597.

6.

Matsuoka, H., H. Obama, M. L. Kelly, T. Matsui, and M. Nakamoto. 2005.
Biphasic functions of the kinase-defective Ephb6 receptor in cell adhesion and
migration. J Biol Chem 280:29355-29363.

7.

Miao, H., K. Strebhardt, E. B. Pasquale, T. L. Shen, J. L. Guan, and B. Wang.
2005. Inhibition of integrin-mediated cell adhesion but not directional cell
migration requires catalytic activity of EphB3 receptor tyrosine kinase. Role of
Rho family small GTPases. J Biol Chem 280:923-932.

101

8.

Stein, E., A. A. Lane, D. P. Cerretti, H. O. Schoecklmann, A. D. Schroff, R. L.
Van Etten, and T. O. Daniel. 1998. Eph receptors discriminate specific ligand
oligomers to determine alternative signaling complexes, attachment, and
assembly responses. Genes Dev 12:667-678.

9.

Davis, S., N. W. Gale, T. H. Aldrich, P. C. Maisonpierre, V. Lhotak, T. Pawson,
M. Goldfarb, and G. D. Yancopoulos. 1994. Ligands for EPH-related receptor
tyrosine kinases that require membrane attachment or clustering for activity.
Science 266:816-819.

10.

Kullander, K., and R. Klein. 2002. Mechanisms and functions of Eph and ephrin
signalling. Nat Rev Mol Cell Biol 3:475-486.

11.

Ip, N. Y., K. O. Lai, Y. Chen, H. M. Po, K. C. Lok, and K. Gong. 2004.
Identification of the Jak/Stat proteins as novel downstream targets of EphA4
signaling in muscle - Implications in the regulation of acetylcholinesterase
expression. Journal of Biological Chemistry 279:13383-13392.

12.

Carpenter, C. L., and L. C. Cantley. 1996. Phosphoinositide 3-kinase and the
regulation of cell growth. Bba-Rev Cancer 1288:M11-M16.

13.

Flanagan, J. G., and P. Vanderhaeghen. 1998. The ephrins and Eph receptors in
neural development. Annu Rev Neurosci 21:309-345.

14.

Pasquale, E. B., and K. K. Murai. 2003. 'Eph'ective signaling: forward, reverse
and crosstalk. J Cell Sci 116:2823-2832.

15.

Pasquale, E. B. 2008. Eph-ephrin bidirectional signaling in physiology and
disease. Cell 133:38-52.

102

16.

Anderson, D. J., H. U. Wang, and Z. F. Chen. 1998. Molecular distinction and
angiogenic interaction between embryonic arteries and veins revealed by ephrinB2 and its receptor Eph-B4. Cell 93:741-753.

17.

Arango, D., J. Castano, V. Davalos, and S. Schwartz. 2008. EPH receptors in
cancer. Histol Histopathol 23:1011-1023.

18.

Ireton, R. C., and J. Chen. 2005. EphA2 receptor tyrosine kinase as a promising
target for cancer therapeutics. Curr Cancer Drug Targets 5:149-157.

19.

Landen, C. N., M. S. Kinch, and A. K. Sood. 2005. EphA2 as a target for ovarian
cancer therapy. Expert Opin Ther Targets 9:1179-1187.

20.

Wykosky, J., and W. Debinski. 2008. The EphA2 receptor and ephrinA1 ligand
in solid tumors: function and therapeutic targeting. Mol Cancer Res 6:1795-1806.

21.

Zhuang, G., D. M. Brantley-Sieders, D. Vaught, J. Yu, L. Xie, S. Wells, D.
Jackson, R. Muraoka-Cook, C. Arteaga, and J. Chen. 2010. Elevation of receptor
tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res
70:299-308.

22.

Huang, F., K. Reeves, X. Han, C. Fairchild, S. Platero, T. W. Wong, F. Lee, P.
Shaw, and E. Clark. 2007. Identification of candidate molecular markers
predicting sensitivity in solid tumors to dasatinib: rationale for patient selection.
Cancer Res 67:2226-2238.

23.

Wang, X. D., K. Reeves, F. R. Luo, L. A. Xu, F. Lee, E. Clark, and F. Huang.
2007. Identification of candidate predictive and surrogate molecular markers for
dasatinib in prostate cancer: rationale for patient selection and efficacy
monitoring. Genome Biol 8:R255.

103

24.

Kandpal, R. P., and B. P. Fox. 2004. Invasiveness of breast carcinoma cells and
transcript profile: Eph receptors and ephrin ligands as molecular markers of
potential diagnostic and prognostic application. Biochem Bioph Res Co 318:882892.

25.

Lawrenson, I. D., S. H. Wimmer-Kleikamp, P. Lock, S. M. Schoenwaelder, M.
Down, A. W. Boyd, P. F. Alewood, and M. Lackmann. 2002. Ephrin-A5 induces
rounding, blebbing and de-adhesion of EphA3-expressing 293T and melanoma
cells by CrkII and Rho-mediated signalling. J Cell Sci 115:1059-1072.

26.

Easty, D. J., S. P. Hill, M. Y. Hsu, M. E. Fallowfield, V. A. Florenes, M. Herlyn,
and D. C. Bennett. 1999. Up-regulation of ephrin-A1 during melanoma
progression. Int J Cancer 84:494-501.

27.

Kinch, M. S., J. Walker-Daniels, K. Coffman, M. Azimi, J. S. Rhim, D. G.
Bostwick, P. Snyder, B. J. Kerns, and D. J. Waters. 1999. Overexpression of the
EphA2 tyrosine kinase in prostate cancer. Prostate 41:275-280.

28.

Boyd, A. W., and M. Lackmann. 2001. Signals from Eph and ephrin proteins: a
developmental tool kit. Sci STKE 2001:re20.

29.

Holder, N., L. Durbin, C. Brennan, K. Shiomi, J. Cooke, A. Barrios, S.
Shanmugalingam, B. Guthrie, and R. Lindberg. 1998. Eph signaling is required
for segmentation and differentiation of the somites. Gene Dev 12:3096-3109.

30.

Cheng, H. J., M. Nakamoto, A. D. Bergemann, and J. G. Flanagan. 1995.
Complementary Gradients in Expression and Binding of Elf-1 and Mek4 in
Development of the Topographic Retinotectal Projection Map. Cell 82:371-381.

104

31.

Chen, J., N. Cheng, and D. M. Brantley. 2002. The ephrins and Eph receptors in
angiogenesis. Cytokine Growth F R 13:75-85.

32.

Kumar, S. R., J. S. Seehnet, E. J. Ley, J. Singh, V. Krasnoperov, R. Liu, P. K.
Manchanda, R. D. Ladner, D. Hawes, F. A. Weaver, R. W. Beart, G. Singh, C.
Nguyen, M. Kahn, and P. S. Gill. 2009. Preferential induction of EphB4 over
EphB2 and its implication in colorectal cancer progression (vol 69, pg 3736,
2009). Cancer Research 69:4554-4554.

33.

Gill, P. S., S. R. Kumar, J. Singh, G. B. Xia, V. Krasnoperov, L. Hassanieh, E. J.
Ley, J. Scehnet, N. G. Kumar, D. Hawes, M. F. Press, and F. A. Weaver. 2006.
Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol
169:279-293.

34.

Bergemann, A. D., and M. Nakamoto. 2002. Diverse roles for the Eph family of
receptor tyrosine kinases in carcinogenesis. Microsc Res Techniq 59:58-67.

35.

Xiong, C., M. Huang, R. Zhang, S. Song, W. Lu, L. Flores, 2nd, J. Gelovani, and
C. Li. 2011. In vivo small-animal PET/CT of EphB4 receptors using

64

Cu-

labeled peptide. J Nucl Med 52:241-248.
36.

Zhang, R., C. Xiong, M. Huang, M. Zhou, Q. Huang, X. Wen, D. Liang, and C.
Li. 2011. Peptide-conjugated polymeric micellar nanoparticles for Dual SPECT
and optical imaging of EphB4 receptors in prostate cancer xenografts.
Biomaterials 32:5872-5879.

37.

Pasquale, E. B., N. K. Noren, M. Lu, A. L. Freeman, and M. Koolpe. 2004.
Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor
growth. P Natl Acad Sci USA 101:5583-5588.

105

38.

Xia, G., S. R. Kumar, R. Masood, S. Zhu, R. Reddy, V. Krasnoperov, D. I. Quinn,
S. M. Henshall, R. L. Sutherland, J. K. Pinski, S. Daneshmand, M. Buscarini, J. P.
Stein, C. Zhong, D. Broek, P. Roy-Burman, and P. S. Gill. 2005. EphB4
expression and biological significance in prostate cancer. Cancer Res 65:46234632.

39.

Lee, Y. C., J. R. Perren, E. L. Douglas, M. P. Raynor, M. A. Bartley, P. G. Bardy,
and S. A. Stephenson. 2005. Investigation of the expression of the EphB4
receptor tyrosine kinase in prostate carcinoma. Bmc Cancer 5:119.

40.

Stephenson, S. A., S. Slomka, E. L. Douglas, P. J. Hewett, and J. E. Hardingham.
2001. Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer.
BMC Mol Biol 2:15.

41.

Vajkoczy, P., R. Erber, U. Eichelsbacher, V. Powajbo, T. Korn, V. Djonov, J. H.
Lin, H. P. Hammes, R. Grobholz, and A. Ullrich. 2006. EphB4 controls blood
vascular morphogenesis during postnatal angiogenesis. Embo J 25:628-641.

42.

Bakker, W. H., E. P. Krenning, J. C. Reubi, W. A. Breeman, B. Setyono-Han, M.
de Jong, P. P. Kooij, C. Bruns, P. M. van Hagen, P. Marbach. 1991. In vivo
application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin
receptor-positive tumors in rats. Life Sci 49:1593-1601.

43.

Hammond, P. J., A. F. Wade, M. E. Gwilliam, A. M. Peters, M. J. Myers, S. G.
Gilbey, S. R. Bloom, and J. Calam. 1993. Amino acid infusion blocks renal
tubular uptake of an indium-labelled somatostatin analogue. Br J Cancer
67:1437-1439.

106

44.

Haubner, R., and C. Decristoforo. 2009. Radiolabelled RGD peptides and
peptidomimetics for tumour targeting. Front Biosci 14:872-886.

45.

Hargreaves, R. 2002. Imaging substance P receptors (NK1) in the living human
brain using positron emission tomography. J Clin Psychiatry 63 Suppl 11:18-24.

46.

Chen, J., Z. Cheng, T. J. Hoffman, S. S. Jurisson, and T. P. Quinn. 2000.
Melanoma-targeting properties of (99m)technetium-labeled cyclic alphamelanocyte-stimulating hormone peptide analogues. Cancer Res 60:5649-5658.

47.

Blower, P. J., M. R. Puncher, A. G. Kettle, S. George, S. Dorsch, A. Leak, L. H.
Naylor, and M. J. O'Doherty. 1998. Iodine-123 salmon calcitonin, an imaging
agent for calcitonin receptors: synthesis, biodistribution, metabolism and
dosimetry in humans. Eur J Nucl Med 25:101-108.

48.

Liu, Y., D. Abendschein, G. E. Woodard, R. Rossin, K. McCommis, J. Zheng, M.
J. Welch, and P. K. Woodard. 2010. Molecular imaging of atherosclerotic plaque
with (64)Cu-labeled natriuretic peptide and PET. J Nucl Med 51:85-91.

49.

Schottelius, M., and H. J. Wester. 2009. Molecular imaging targeting peptide
receptors. Methods 48:161-177.

50.

Koolpe, M., R. Burgess, M. Dail, and E. B. Pasquale. 2005. EphB receptorbinding peptides identified by phage display enable design of an antagonist with
ephrin-like affinity. J Biol Chem 280:17301-17311.

51.

Wester, H. J. 2007. Nuclear imaging probes: from bench to bedside. Clin Cancer
Res 13:3470-3481.

52.

Blankenberg, F. G., and H. W. Strauss. 2002. Nuclear medicine applications in
molecular imaging. J Magn Reson Imaging 16:352-361.

107

53.

Blankenberg, F. G., and H. W. Strauss. 2007. Nuclear medicine applications in
molecular imaging: 2007 update. Q J Nucl Med Mol Imaging 51:99-110.

54.

Weissleder, R., and U. Mahmood. 2001. Molecular imaging. Radiology 219:316333.

55.

Wang, W., S. Ke, S. Kwon, S. Yallampalli, A. G. Cameron, K. E. Adams, M. E.
Mawad, and E. M. Sevick-Muraca. 2007. A new optical and nuclear dual-labeled
imaging agent targeting interleukin 11 receptor alpha-chain. Bioconjug Chem
18:397-402.

56.

Weissleder, R., and V. Ntziachristos. 2003. Shedding light onto live molecular
targets. Nat Med 9:123-128.

57.

Dzik-Jurasz, A. S. 2003. Molecular imaging in vivo: an introduction. Br J Radiol
76 Spec No 2:S98-109.

58.

Grinvald, A., R. D. Frostig, E. Lieke, and R. Hildesheim. 1988. Optical imaging
of neuronal activity. Physiol Rev 68:1285-1366.

59.

Gibson, A. P., J. C. Hebden, and S. R. Arridge. 2005. Recent advances in diffuse
optical imaging. Phys Med Biol 50:R1-43.

60.

Bremer, C., V. Ntziachristos, and R. Weissleder. 2003. Optical-based molecular
imaging: contrast agents and potential medical applications. Eur Radiol 13:231243.

61.

Hielscher, A. H. 2005. Optical tomographic imaging of small animals. Curr Opin
Biotechnol 16:79-88.

62.

Licha, K., and C. Olbrich. 2005. Optical imaging in drug discovery and
diagnostic applications. Adv Drug Deliv Rev 57:1087-1108.

108

63.

Niell, C. M., and S. J. Smith. 2004. Live optical imaging of nervous system
development. Annu Rev Physiol 66:771-798.

64.

Luker, G. D., and K. E. Luker. 2008. Optical imaging: current applications and
future directions. J Nucl Med 49:1-4.

65.

Cerussi, A., D. Hsiang, N. Shah, R. Mehta, A. Durkin, J. Butler, and B. J.
Tromberg. 2007. Predicting response to breast cancer neoadjuvant chemotherapy
using diffuse optical spectroscopy. Proc Natl Acad Sci U S A 104:4014-4019.

66.

Rao, J., A. Dragulescu-Andrasi, and H. Yao. 2007. Fluorescence imaging in vivo:
recent advances. Curr Opin Biotechnol 18:17-25.

67.

Frangioni, J. V. 2003. In vivo near-infrared fluorescence imaging. Curr Opin
Chem Biol 7:626-634.

68.

Ntziachristos, V., C. Bremer, and R. Weissleder. 2003. Fluorescence imaging
with near-infrared light: new technological advances that enable in vivo
molecular imaging. Eur Radiol 13:195-208.

69.

Reich, G. 2005. Near-infrared spectroscopy and imaging: basic principles and
pharmaceutical applications. Adv Drug Deliv Rev 57:1109-1143.

70.

Mahmood, U., and R. Weissleder. 2003. Near-infrared optical imaging of
proteases in cancer. Mol Cancer Ther 2:489-496.

71.

Massoud, T. F., and S. S. Gambhir. 2003. Molecular imaging in living subjects:
seeing fundamental biological processes in a new light. Genes & Development
17:545-580.

72.

Louie, A. Multimodality imaging probes: design and challenges. Chem Rev
110:3146-3195.

109

73.

Melancon, M. P., W. Lu, Z. Yang, R. Zhang, Z. Cheng, A. M. Elliot, J. Stafford,
T. Olson, J. Z. Zhang, and C. Li. 2008. In vitro and in vivo targeting of hollow
gold nanoshells directed at epidermal growth factor receptor for photothermal
ablation therapy. Mol Cancer Ther 7:1730-1739.

74.

Schwartzberg, A. M., T. Y. Olson, C. E. Talley, and J. Z. Zhang. 2006. Synthesis,
characterization, and tunable optical properties of hollow gold nanospheres. J
Phys Chem B 110:19935-19944.

75.

Liang, H. P., L. J. Wan, C. L. Bai, and L. Jiang. 2005. Gold hollow nanospheres:
tunable surface plasmon resonance controlled by interior-cavity sizes. J Phys
Chem B 109:7795-7800.

76.

Vogel, A., and V. Venugopalan. 2003. Mechanisms of pulsed laser ablation of
biological tissues. Chem Rev 103:577-644.

77.

Amin, Z., J. J. Donald, A. Masters, R. Kant, A. C. Steger, S. G. Bown, and W. R.
Lees. 1993. Hepatic metastases: interstitial laser photocoagulation with real-time
US monitoring and dynamic CT evaluation of treatment. Radiology 187:339-347.

78.

Fiedler, V. U., H. J. Schwarzmaier, F. Eickmeyer, F. P. Muller, C. Schoepp, and
P. R. Verreet. 2001. Laser-induced interstitial thermotherapy of liver metastases
in an interventional 0.5 Tesla MRI system: technique and first clinical
experiences. J Magn Reson Imaging 13:729-737.

79.

Nolsoe, C. P., S. Torp-Pedersen, F. Burcharth, T. Horn, S. Pedersen, N. E.
Christensen, E. S. Olldag, P. H. Andersen, S. Karstrup, T. Lorentzen. 1993.
Interstitial hyperthermia of colorectal liver metastases with a US-guided NdYAG laser with a diffuser tip: a pilot clinical study. Radiology 187:333-337.

110

80.

Au, L., D. Zheng, F. Zhou, Z. Y. Li, X. Li, and Y. Xia. 2008. A quantitative
study on the photothermal effect of immuno gold nanocages targeted to breast
cancer cells. ACS Nano 2:1645-1652.

81.

Chen, J., D. Wang, J. Xi, L. Au, A. Siekkinen, A. Warsen, Z. Y. Li, H. Zhang, Y.
Xia, and X. Li. 2007. Immuno gold nanocages with tailored optical properties for
targeted photothermal destruction of cancer cells. Nano Lett 7:1318-1322.

82.

Dickerson, E. B., E. C. Dreaden, X. Huang, I. H. El-Sayed, H. Chu, S.
Pushpanketh, J. F. McDonald, and M. A. El-Sayed. 2008. Gold nanorod assisted
near-infrared plasmonic photothermal therapy (PPTT) of squamous cell
carcinoma in mice. Cancer Lett 269:57-66.

83.

Hirsch, L. R., R. J. Stafford, J. A. Bankson, S. R. Sershen, B. Rivera, R. E. Price,
J. D. Hazle, N. J. Halas, and J. L. West. 2003. Nanoshell-mediated near-infrared
thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad
Sci U S A 100:13549-13554.

84.

Loo, C., A. Lowery, N. Halas, J. West, and R. Drezek. 2005. Immunotargeted
nanoshells for integrated cancer imaging and therapy. Nano Lett 5:709-711.

85.

Lu, W., C. Xiong, G. Zhang, Q. Huang, R. Zhang, J. Z. Zhang, and C. Li. 2009.
Targeted photothermal ablation of murine melanomas with melanocytestimulating hormone analog-conjugated hollow gold nanospheres. Clin Cancer
Res 15:876-886.

86.

Park, J. H., G. von Maltzahn, M. J. Xu, V. Fogal, V. R. Kotamraju, E. Ruoslahti,
S. N. Bhatia, and M. J. Sailor. 2009. Cooperative nanomaterial system to
sensitize, target, and treat tumors. Proc Natl Acad Sci U S A 107:981-986.

111

87.

Park, J. H., G. von Maltzahn, M. J. Xu, V. Fogal, V. R. Kotamraju, E. Ruoslahti,
S. N. Bhatia, and M. J. Sailor. 2010. Cooperative nanomaterial system to
sensitize, target, and treat tumors. Proc Natl Acad Sci U S A 107:981-986.

88.

Lowery, A. R., A. M. Gobin, E. S. Day, N. J. Halas, and J. L. West. 2006.
Immunonanoshells for targeted photothermal ablation of tumor cells. Int J
Nanomedicine 1:149-154.

89.

Bernardi, R. J., A. R. Lowery, P. A. Thompson, S. M. Blaney, and J. L. West.
2008. Immunonanoshells for targeted photothermal ablation in medulloblastoma
and glioma: an in vitro evaluation using human cell lines. J Neurooncol 86:165172.

90.

Xiong, C., M. Huang, R. Zhang, S. Song, W. Lu, L. Flores, 2nd, J. Gelovani, and
C. Li. In vivo small-animal PET/CT of EphB4 receptors using

64

Cu-labeled

peptide. J Nucl Med 52:241-248.
91.

Zhang, R., C. Xiong, M. Huang, M. Zhou, Q. Huang, X. Wen, D. Liang, and C.
Li. Peptide-conjugated polymeric micellar nanoparticles for Dual SPECT and
optical imaging of EphB4 receptors in prostate cancer xenografts. Biomaterials
32:5872-5879.

92.

Cooper, M. A. 2002. Optical biosensors in drug discovery. Nature Reviews Drug
Discovery 1:515.

93.

Pasquale, E. B., and N. K. Noren. 2007. Paradoxes of the EphB4 receptor in
cancer. Cancer Research 67:3994-3997.

94.

Kuhn, P., J. E. Chrencik, A. Brooun, M. I. Recht, M. L. Kraus, M. Koolpe, A. R.
Kolatkar, R. H. Bruce, G. Martiny-Baron, H. Widmer, and E. B. Pasquale. 2006.

112

Structure and thermodynamic characterization of the EphB4/ephrin-B2
antagonist peptide complex reveals the determinants for receptor specificity.
Structure 14:321-330.
95.

Ellis, L. M., W. B. Liu, S. A. Ahmad, Y. D. Jung, N. Reinmuth, F. Fan, and C. D.
Bucana. 2002. Coexpression of ephrin-Bs and their receptors in colon carcinoma.
Cancer 94:934-939.

96.

Takakura, N., X. Huang, Y. Yamada, H. Kidoya, H. Naito, Y. Nagahama, L.
Kong, S. Y. Katoh, W. F. Li, and M. Ueno. 2007. EphB4 overexpression in B16
melanoma cells affects arterial-venous patterning in tumor angiogenesis. Cancer
Research 67:9800-9808.

97.

Jain, R. K. 1998. Delivery of molecular and cellular medicine to solid tumors. J
Control Release 53:49-67.

98.

Hong, S. Y., J. E. Oh, and K. H. Lee. 1999. Effect of D-amino acid substitution
on the stability, the secondary structure, and the activity of membrane-active
peptide. Biochem Pharmacol 58:1775-1780.

99.

Yamasaki, M., K. Shibata, T. Suzawa, S. Soga, T. Mizukami, K. Yamada, and N.
Hanai. 2003. Improvement of biological activity and proteolytic stability of
peptides by coupling with a cyclic peptide. Bioorg Med Chem Lett 13:2583-2586.

100.

Rusckowski, M., T. Qu, S. Gupta, A. Ley, and D. J. Hnatowich. 2001. A
comparison in monkeys of (99m)Tc labeled to a peptide by 4 methods. J Nucl
Med 42:1870-1877.

113

101.

Tsai, S. W., L. Li, L. E. Williams, A. L. Anderson, A. A. Raubitschek, and J. E.
Shively. 2001. Metabolism and renal clearance of 111In-labeled DOTAconjugated antibody fragments. Bioconjug Chem 12:264-270.

102.

DePinho, R. A., F. B. Furnari, T. Fenton, R. M. Bachoo, A. Mukasa, J. M.
Stommel, A. Stegh, W. C. Hahn, K. L. Ligon, D. N. Louis, C. Brennan, L. Chin,
and W. K. Cavenee. 2007. Malignant astrocytic glioma: genetics, biology, and
paths to treatment. Gene Dev 21:2683-2710.

103.

Wen, P. Y., and S. Kesari. 2008. Malignant gliomas in adults. New Engl J Med
359:492-507.

104.

Hsu, A. R., W. Cai, A. Veeravagu, K. A. Mohamedali, K. Chen, S. Kim, H.
Vogel, L. C. Hou, V. Tse, M. G. Rosenblum, and X. Chen. 2007. Multimodality
molecular imaging of glioblastoma growth inhibition with vasculature-targeting
fusion toxin VEGF121/rGel. J Nucl Med 48:445-454.

105.

Hsu, A. R., L. C. Hou, A. Veeravagu, J. M. Greve, H. Vogel, V. Tse, and X.
Chen. 2006. In vivo near-infrared fluorescence imaging of integrin alphavbeta3
in an orthotopic glioblastoma model. Mol Imaging Biol 8:315-323.

106.

McCann, C. M., P. Waterman, J. L. Figueiredo, E. Aikawa, R. Weissleder, and J.
W. Chen. 2009. Combined magnetic resonance and fluorescence imaging of the
living mouse brain reveals glioma response to chemotherapy. Neuroimage
45:360-369.

107.

Adams, K. E., S. Ke, S. Kwon, F. Liang, Z. Fan, Y. Lu, K. Hirschi, M. E. Mawad,
M. A. Barry, and E. M. Sevick-Muraca. 2007. Comparison of visible and near-

114

infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer.
J Biomed Opt 12:024017.
108.

Barker, F. G., 2nd, and S. M. Chang. 2006. Improving resection of malignant
glioma. Lancet Oncol 7:359-360.

109.

Laws, E. R., I. F. Parney, W. Huang, F. Anderson, A. M. Morris, A. Asher, K. O.
Lillehei, M. Bernstein, H. Brem, A. Sloan, M. S. Berger, and S. Chang. 2003.
Survival following surgery and prognostic factors for recently diagnosed
malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 99:467473.

110.

Stummer, W., U. Pichlmeier, T. Meinel, O. D. Wiestler, F. Zanella, and H. J.
Reulen. 2006. Fluorescence-guided surgery with 5-aminolevulinic acid for
resection of malignant glioma: a randomised controlled multicentre phase III trial.
Lancet Oncol 7:392-401.

111.

Yang, Z., S. Zheng, W. J. Harrison, J. Harder, X. Wen, J. G. Gelovani, A. Qiao,
and C. Li. 2007. Long-circulating near-infrared fluorescence core-cross-linked
polymeric micelles: synthesis, characterization, and dual nuclear/optical imaging.
Biomacromolecules 8:3422-3428.

112.

Maeda, H. 2001. The enhanced permeability and retention (EPR) effect in tumor
vasculature: the key role of tumor-selective macromolecular drug targeting. Adv
Enzyme Regul 41:189-207.

113.

Matsumura, Y., and H. Maeda. 1986. A new concept for macromolecular
therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation
of proteins and the antitumor agent smancs. Cancer Res 46:6387-6392.

115

114.

Poon, R. T., and N. Borys. 2009. Lyso-thermosensitive liposomal doxorubicin: a
novel approach to enhance efficacy of thermal ablation of liver cancer. Expert
Opin Pharmacother 10:333-343.

115.

Vasey, P. A., S. B. Kaye, R. Morrison, C. Twelves, P. Wilson, R. Duncan, A. H.
Thomson, L. S. Murray, T. E. Hilditch, T. Murray, S. Burtles, D. Fraier, E.
Frigerio, and J. Cassidy. 1999. Phase I clinical and pharmacokinetic study of
PK1

[N-(2-hydroxypropyl)methacrylamide

copolymer

doxorubicin]:

first

member of a new class of chemotherapeutic agents-drug-polymer conjugates.
Cancer Research Campaign Phase I/II Committee. Clin Cancer Res 5:83-94.
116.

DeNardo, S. J., Z. S. Yao, K. S. Lam, A. M. Song, P. A. Burke, G. R. Mirick, K.
R. Lamborn, R. T. O'Donnell, and G. L. DeNardo. 2003. Effect of molecular size
of pegylated peptide on the pharmacokinetics and tumor targeting in lymphomabearing mice. Clinical Cancer Research 9:3854s-3864s.

117.

DeNardo, S. J., Z. Yao, G. L. DeNardo, A. Song, D. L. Kukis, G. R. Mirick, K. R.
Lamborn, R. T. O'Donnell, and K. S. Lam. 2002. Effect of molecular size of
pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma
bearing mice. Journal of Nuclear Medicine 43:93p-93p.

118.

Song, S., C. Xiong, M. Zhou, W. Lu, Q. Huang, G. Ku, J. Zhao, L. G. Flores, Jr.,
Y. Ni, and C. Li. 2011. Small-animal PET of tumor damage induced by
photothermal ablation with 64Cu-bis-DOTA-hypericin. J Nucl Med 52:792-799.

116

VITA
Miao Huang was born at Suzhou, China on May 15th, 1976, the son of Zhicai Huang
and Ji Hu. After completing his high school at the Suzhou High School, JiangSu, China
in 1994, he entered Suzhou Medical College in Suzhou, China. He received the degree
of Bachelor of Mecicine with a major in clinical medicine from Suzhou medical college
in July, 1999. In September 2004, he entered Dr. Feng Wang-Johanning’s lab to study
and received the degree of Master of Science with a major in Cancer Biology from
University of Texas health Science Center at Houston in July, 2006. Then he admitted
into Ph.D program in the same school (Advisor, Chun Li, Ph.D.).

Permanent address:
zhong Jun xin cun building 14, Apt 205
Suzhou
JiangSu, China, 215000.

117

